2024/02/15 更新

写真a

ヨコセ　ノリオ
横瀨　紀夫
Yokose Norio
所属
千葉北総病院 血液内科 病院教授
職名
病院教授
外部リンク

学位

  • 博士(医学) （ 日本医科大学 ）

研究キーワード

  • Hematological malignancy

  • Hematological disease

  • 造血器疾患

  • 血液腫瘍

研究分野

  • ライフサイエンス / 血液、腫瘍内科学

学歴

  • 日本医科大学

    - 1988年

    　 詳細を見る

  • 日本医科大学   医学部   医学

    - 1988年

    　 詳細を見る

    国名： 日本国

    researchmap

経歴

  • 日本医科大学   院血液内科   部長

    2014年4月 - 現在

    　 詳細を見る

  • 日本医科大学   血液内科

    2003年9月 - 現在

    　 詳細を見る

  • Research Associate, Faculty of Medicine,

    1990年 - 2002年

    　 詳細を見る

  • 日本医科大学   血液内科

    1990年 - 2002年

    　 詳細を見る

  • 日本医科大学

    　 詳細を見る

  • 日本医科大学

    　 詳細を見る

  • 日本医科大学 医学部 医学科 千葉北総病院 血液内科

    　 詳細を見る

▼全件表示

所属学協会

論文

  • Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.

    Chikashi Yoshida, Hiroki Yamaguchi, Noriko Doki, Kazunori Murai, Masaki Iino, Yoshihiro Hatta, Makoto Onizuka, Norio Yokose, Katsumichi Fujimaki, Masao Hagihara, Gaku Oshikawa, Kayoko Murayama, Takashi Kumagai, Shinya Kimura, Yuho Najima, Noriyoshi Iriyama, Ikuyo Tsutsumi, Koji Oba, Hiroshi Kojima, Hisashi Sakamaki, Koiti Inokuchi

    International journal of hematology   117 ( 5 )   694 - 705   2023年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Treatment-free remission (TFR) is a new goal for patients with chronic myeloid leukemia in chronic phase (CML-CP) with a sustained deep molecular response (DMR) to treatment with tyrosine kinase inhibitors (TKIs). However, optimal conditions for successful TFR in patients treated with second-generation (2G)-TKIs are not fully defined. In this D-FREE study, treatment discontinuation was attempted in newly diagnosed CML-CP patients treated with the 2G-TKI dasatinib who achieved BCR-ABL1 levels of ≤ 0.0032% (MR4.5) on the international scale (BCR-ABL1IS) and maintained these levels for exactly 1 year. Of the 173 patients who received dasatinib induction therapy for up to 2 years, 123 completed and 60 (48.8%) reached MR 4.5. Among the first 21 patients who maintained MR4.5 for 1 year and discontinued dasatinib, 17 experienced molecular relapse defined as loss of major molecular response (BCR-ABL1IS > 0.1%) confirmed once, or loss of MR4 (BCR-ABL1IS > 0.01%) confirmed on 2 consecutive assessments. The estimated molecular relapse-free survival rate was 16.7% at 12 months. This study was prematurely terminated according to the protocol's safety monitoring criteria. The conclusion was that sustained DMR for just 1 year is insufficient for TFR in CML-CP patients receiving dasatinib for less than a total of 3 years of treatment.

    DOI： 10.1007/s12185-023-03549-3

    PubMed

    researchmap

  • Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study

    Chikashi Yoshida, Hiroki Yamaguchi, Noriko Doki, Kazunori Murai, Masaki Iino, Yoshihiro Hatta, Makoto Onizuka, Norio Yokose, Katsumichi Fujimaki, Masao Hagihara, Gaku Oshikawa, Kayoko Murayama, Takashi Kumagai, Shinya Kimura, Yuho Najima, Noriyoshi Iriyama, Ikuyo Tsutsumi, Koji Oba, Hiroshi Kojima, Hisashi Sakamaki, Koiti Inokuchi

    International Journal of Hematology   2023年

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    Treatment-free remission (TFR) is a new goal for patients with chronic myeloid leukemia in chronic phase (CML-CP) with a sustained deep molecular response (DMR) to treatment with tyrosine kinase inhibitors (TKIs). However, optimal conditions for successful TFR in patients treated with second-generation (2G)-TKIs are not fully defined. In this D-FREE study, treatment discontinuation was attempted in newly diagnosed CML-CP patients treated with the 2G-TKI dasatinib who achieved BCR-ABL1 levels of ≤ 0.0032% (MR4.5) on the international scale (BCR-ABL1IS) and maintained these levels for exactly 1 year. Of the 173 patients who received dasatinib induction therapy for up to 2 years, 123 completed and 60 (48.8%) reached MR 4.5. Among the first 21 patients who maintained MR4.5 for 1 year and discontinued dasatinib, 17 experienced molecular relapse defined as loss of major molecular response (BCR-ABL1IS > 0.1%) confirmed once, or loss of MR4 (BCR-ABL1IS > 0.01%) confirmed on 2 consecutive assessments. The estimated molecular relapse-free survival rate was 16.7% at 12 months. This study was prematurely terminated according to the protocol’s safety monitoring criteria. The conclusion was that sustained DMR for just 1 year is insufficient for TFR in CML-CP patients receiving dasatinib for less than a total of 3 years of treatment.

    DOI： 10.1007/s12185-023-03549-3

    Scopus

    researchmap

  • Successful Treatment of Thrombocytopenia, Anasarca, Fever, Reticulin Myelofibrosis/Renal Insufficiency, and Organomegaly Syndrome Using Plasma Exchange Followed by Rituximab in the Intensive Care Unit. 国際誌

    Yusuke Otsuka, Akihiro Shirakabe, Toshio Asayama, Hirotake Okazaki, Yusaku Shibata, Shota Shigihara, Tomofumi Sawatani, Norio Yokose, Kuniya Asai

    Journal of medical cases   12 ( 12 )   474 - 480   2021年12月

    　詳細を見る

    記述言語：英語  

    Thrombocytopenia, anasarca, fever, reticulin myelofibrosis/renal insufficiency, and organomegaly (TAFRO) syndrome is treated using corticosteroids and/or immunosuppressive agents as first-line therapy. We report the case of a 69-year-old female with TAFRO syndrome in which the patient presented multiple organ failure and steroid resistance, which was successfully treated using plasma exchange (PE) followed by rituximab. Decisions regarding the next treatment, including PE, are urgent for patients with steroid-resistant TAFRO syndrome. Since it is considered that immunosuppressive agents may be removed by PE, the performance of PE before treatment with immunosuppressive agents might be an option for steroid-resistant TAFRO syndrome.

    DOI： 10.14740/jmc3784

    PubMed

    researchmap

  • Clinicopathologic characteristics and A20 mutation in primary thyroid lymphoma

    Yasuko Kuribayashi-Hamada, Mariko Ishibashi, Atsushi Tatsuguchi, Toshio Asayama, Namiko Takada-Okuyama, Asaka Onodera-Kondo, Keiichi Moriya, Takehito Igarashi, Hiroyuki Onose, Sakae Tanosaki, Norio Yokose, Hiroki Yamaguchi, Hideto Tamura

    Journal of Nippon Medical School   2021年

    　詳細を見る

    掲載種別：研究論文（学術雑誌）   出版者・発行元：Medical Association of Nippon Medical School  

    DOI： 10.1272/jnms.jnms.2022_89-305

    researchmap

  • Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations 査読 国際誌

    Koiti Inokuchi, Kazutaka Nakayama, Tetsuzo Tauchi, Tomoiku Takaku, Norio Yokose, Hiroki Yamaguchi, Takashi Kumagai, Norio Komatsu, Kazuma Ohyashiki

    Leukemia Research   65   74 - 79   2018年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier Ltd  

    © 2018 Elsevier Ltd We analyzed the clinical responses to thyrosine kinase inhibitors (TKIs) and the molecular and cytogenetic characteristics of 18 chronic myeloid leukemia (CML) patients with 3-way chromosomal translocations. The patients were 14 men and 4 women, aged 23–75 years (median 57 years). The Sokal risk was low in 12 patients, intermediate in 4 patients, and high in 2 patients. Newly identified translocation breakpoints were seen in 7 of the 18 patients. Three patients had the same breakpoints of t(9;22;11)(q34;q11.2;q23). The best responses to TKIs were partial cytogenic response (PCyR) in 2 patients, complete cytogenic response (CCyR) in 3 patients, molecular response (MR) 3.0 in 7 patients, MR 4.0 in 3 patients, and MR 4.5 or higher in 3 patients. A total of 66.7% of patients did not achieve MR 4.0 or higher. In 3 patients in whom TKIs resulted in MR 4.5 or higher for more than 2 years, TKI treatment was discontinued. However, all of them exhibited a loss of MR3.0, at 2, 6, and 20 months after the discontinuation of treatment, respectively, and TKI treatment needed to be restarted. According to Kaplan-Meier survival curve analysis, the overall survival (OS) was 100 months in 56% of the patients. The 60-months cumulative incidences of CCyR, MR3.0, MR4.0 and MR4.5 were 88.9%, 72.2%, 33.3%, and 16.7%, respectively. In the 11 analyzable patients, the BCR-ABL1 mRNA subtype was e14a2 type in 4 patients and e13a2 type in 7 patients.

    DOI： 10.1016/j.leukres.2018.01.005

    Web of Science

    Scopus

    PubMed

    researchmap

  • Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes 査読

    Toshio Asayama, Mariko Ishibashi, Hideto Tamura, Yasuko Hamada, Namiko Okuyama, Asaka Onodera, Akiko Yamada, Keiichi Moriya, Norio Yokose, Koiti Inokuchi

    BLOOD   126 ( 23 )   2015年12月

    　詳細を見る

    記述言語：英語   出版者・発行元：AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Evaluation of the enhanced International Prognostic Index (NCCN-IPI) for cases with diffuse large B-cell lymphoma 査読

    Akiko Yamada, Hideto Tamura, Toshio Asayama, Keiichi Moriya, Namiko Okuyama, Asaka Kondo-Onodera, Yasuko Hamada, Mariko Ishibashi, Norio Yokose, Sakae Tanosaki, Koiti Inokuchi

    [Rinshō ketsueki] The Japanese journal of clinical hematology   56 ( 7 )   915 - 918   2015年7月

    　詳細を見る

    記述言語：日本語   掲載種別：研究論文（学術雑誌）  

    The NCCN-International Prognostic Index (IPI) is reported to be more powerful than the former IPI for predicting survival in the rituximab era. To evaluate the NCCN-IPI in our institutions, we analyzed 188 patients with diffuse large B-cell lymphoma treated with rituximab plus CHOP or THP-COP chemotherapy. The 5-year overall survival rates of patients with low, low-intermediate, high-intermediate, and high risk were 90%, 76%, 64%, and 34%, respectively. Although there was no difference in overall survival between patients 61-75 and those >75 years of age, the NCCN-IPI is useful for classifying prognostically relevant subgroups of Japanese patients.

    DOI： 10.11406/rinketsu.56.915

    Scopus

    PubMed

    researchmap

  • Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia 査読 国際誌

    Matteo G. Della Porta, Cristina Picone, Annamaria Tenore, Norio Yokose, Luca Malcovati, Mario Cazzola, Kiyoyuki Ogata

    Haematologica   99 ( 1 )   8 - 10   2014年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：FERRATA STORTI FOUNDATION  

    DOI： 10.3324/haematol.2013.097188

    Web of Science

    Scopus

    PubMed

    researchmap

  • der(14)t(8:14)(q24.1;q32)t(8:22)(q24.1;q11.2)を伴うバーキット白血病(Burkitt leukemia with der(14)t(8:14)(q24.1:q32)t(8:22)(q24.1:q11.2))

    Yokose Norio, Hirakawa Tsuneaki, Dan Kazuo, Inokuchi Koichi

    臨床血液   52 ( 9 )   1193 - 1193   2011年9月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • TKI投与時の複合three-way転座によるCMLの臨床特性(Chrinical characteristics of CML with a complex three-way translocation in an era of TKls therapy)

    Okamoto Muneo, Yamaguchi Hiroki, Hirakawa Tsuneaki, Wakita Satoshi, Yokose Norio, Dan Kazuo, Inokuchi Koichi

    臨床血液   52 ( 9 )   1200 - 1200   2011年9月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations 査読

    Koiti Inokuchi, Satoshi Wakita, Tsuneaki Hirakawa, Hayato Tamai, Norio Yokose, Hiroki Yamaguchi, Kazuo Dan

    International Journal of Hematology   94 ( 3 )   255 - 260   2011年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：SPRINGER TOKYO  

    Recently, RCSD1 was identified as a novel gene fusion partner of the ABL1 gene. The RCSD1 gene, located at 1q23, is involved in t(1;9)(q23;q34) translocation in acute B lymphoblastic leukemia. Here we describe RCSD1-ABL1-positive B-cell acute lymphoblastic leukemia (ALL) followed by rapid clonal evolution exhibiting three rare reciprocal translocations. We performed breakpoint analysis of the transcript expressed by the RCSD1- ABL1 fusion gene. RT-PCR and sequence analyses detected transcription of a single RCSD1-ABL1 fusion gene variant, which had breakpoints in exon 3 of RCSD1 and exon 4 of ABL1. The RCSD1 portion of the RCSD1- ABL1 fusion transcript consists of exons 1, 2, and 3. Tyrosine kinase inhibitors, imatinib and dasatinib, coadministered with dexamethasone achieved transient clinical effects in the present RCSD1-ABL1-positive ALL. However, leukemic cells rapidly became refractory to this treatment following the subsequent development of three additional reciprocal chromosomal translocations, t(5;16)(q33;q24), dic(18;20)(p11.2;q11.2) and t(10;19) (q24;p13.3). The present RCSD1-ABL1-positive ALL may represent a state of high chromosomal instability.

    DOI： 10.1007/s12185-011-0910-z

    Web of Science

    Scopus

    PubMed

    researchmap

  • Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leaukemia by the TARGET system

    TAUCHI T

    Leuk Res   35 ( 5 )   585 - 590   2011年5月

    　詳細を見る

    記述言語：英語  

    researchmap

  • Prognostic Significance of WT1 mRNA and Anti-WT1 Antibody Levels in Peripheral Blood in Patients with Myelodysplastic Syndromes. 査読

    Hideto Tamura, Kazuo Dan, Norio Yokose, Rika Iwakiri, Masatsugu Ohta, Hisashi Sakamaki, Kaoru Tohyama, Kondo Asaka, Hideya Hyodo, Kyoko Nakamura, Taishi Yamashita, Olga A. Elisseeva, Yoshihiro Oka, Yusuke Oji, Haruo Sugiyama, Kiyoyuki Ogata

    BLOOD   114 ( 22 )   1470 - 1470   2009年11月

    　詳細を見る

    記述言語：英語   出版者・発行元：AMER SOC HEMATOLOGY  

    DOI： 10.1016/S0145-2126(09)70128-6

    Web of Science

    researchmap

  • Picture in clinical hematology no. 36: Case of primary effusion lymphoma with severe pericardial effusion 査読

    Tsuneaki Hirakawa, Norio Yokose, Kazuo Dan, Koichi Iguchi

    [Rinshō ketsueki] The Japanese journal of clinical hematology   50 ( 4 )   215 - 216   2009年4月

    　詳細を見る

    記述言語：日本語   掲載種別：研究論文（学術雑誌）  

    Scopus

    PubMed

    researchmap

  • Analysis of triglyceride value in the diagnosis and treatment response of secondary hemophagocytic syndrome 査読

    Muneo Okamoto, Hiroki Yamaguchi, Yasushi Isobe, Norio Yokose, Taro Mizuki, Kenji Tajika, Seiji Gomi, Hiroyuki Hamaguchi, Koiti Inokuchi, Kazuo Oshimi, Kazuo Dan

    Internal Medicine   48 ( 10 )   775 - 781   2009年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：JAPAN SOC INTERNAL MEDICINE  

    Background/Aims: Secondary hemophagocytic syndrome (hemophagocytic lymphohistiocytosis, HLH) follows viral infection, malignant disorders, and autoimmune disease. Criteria for HLH diagnosis, which were proposed in 2004, include hypertriglyceridemia. However, some studies reported the absence of hypertriglyceridemia in patients with secondary HLH, differing from those with primary HLH. Subjects and Methods: In this study, we investigated the presence or absence of hypertriglyceridemia in 28 patients who were diagnosed with secondary HLH between 1997 and 2007 retrospectively. There were no patients undergoing treatment for those with a history of hyperlipidemia. Results: The subjects consisted of 14 patients with lymphoma-associated HLH, 11 with virus-associated HLH, 2 with autoimmune disease-associated HLH, and 1 with post transplantation HLH. In 19 patients (68%), hypertriglyceridemia was noted on diagnosis or during the disease period (mean: 242 mg/dL). Furthermore, the triglyceride (TG) level decreased with the treatment-related amelioration of HLH (mean level before and after treatment: 297 and 136 mg/dL, respectively, p=0.0001). Conclusion: These results suggest that the TG level is useful for diagnosing HLH and evaluating the treatment response. TG measurement is simple and inexpensive; therefore, this parameter can be determined several times to evaluate the treatment response. © 2009 The Japanese Society of Internal Medicine.

    DOI： 10.2169/internalmedicine.48.1677

    Web of Science

    Scopus

    PubMed

    researchmap

  • Importance of Relative Dose Intensity for Survival in Diffuse Large B-Cell Lymphoma Patients Treated with CHOP-Like Regimen. 査読

    Tsuneaki Hirakawa, Hiroki Yamaguchi, Seiji Gomi, Norio Yokose, Koiti Inokuchi, Kazuo Dan

    BLOOD   112 ( 11 )   1233 - 1233   2008年11月

    　詳細を見る

    記述言語：英語   出版者・発行元：AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes: A Prospective Validation Study in Low-Risk Patients with Normal Karyotype 査読

    Kiyoyuki Ogata, Matteo G. Della Porta, Luca Malcovati, Cristina Picone, Norio Yokose, Akira Matsuda, Taishi Yamashita, Hideto Tamura, Junichi Tsukada, Kazuo Dan, Mario Cazzola

    BLOOD   112 ( 11 )   1243 - 1243   2008年11月

    　詳細を見る

    記述言語：英語   出版者・発行元：AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Expression of WT-1 mRNA in Peripheral Blood from Myelodysplastic Syndromes 査読

    Hideto Tamura, Kazuo Dan, Norio Yokose, Rika Iwakiri, Masatsugu Ohta, Hisashi Sakamaki, Kaoru Tohyama, Asaka Kondo, Kyoko Nakamura, Taishi Yamashita, Takashi Tsuji, Kiyoyuki Ogata

    BLOOD   112 ( 11 )   1244 - 1244   2008年11月

    　詳細を見る

    記述言語：英語   出版者・発行元：AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Cell cycle analysis of blasts in patients with myelodysplastic syndromes who received granulocyte colony-stimulating factor 査読

    E An, K Ogata, K Kamikubo, H Tamura, N Yokose, K Dan, T Nomura

    MYELODYSPLASTIC SYNDROMES   1080   361 - 368   1995年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（国際会議プロシーディングス）   出版者・発行元：ELSEVIER SCIENCE PUBL B V  

    Web of Science

    researchmap

  • Effects of cytokines on lymphocyte cytotoxicity in patients with myelodysplastic syndromes 査読

    H Tamura, K Ogata, N Yokose, E An, A Tatsukuchi, K Kamikubo, K Dan, H Hamaguchi, H Sakamaki, Y Onozawa, SC Clark, T Nomura

    MYELODYSPLASTIC SYNDROMES   1080   369 - 373   1995年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（国際会議プロシーディングス）   出版者・発行元：ELSEVIER SCIENCE PUBL B V  

    Web of Science

    researchmap

  • Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes 査読

    K. Ogata, N. Yokose, T. Ito, E. An, H. Tamura, K. Dan, H. Hamaguchi, H. Sakamaki, Y. Onozawa, T. Nomura

    British Journal of Haematology   86 ( 3 )   562 - 567   1994年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：BLACKWELL SCIENCE LTD  

    The therapeutic potential of interleukin 2 (IL-2) for myelodsplastic syndromes (MDS) was evaluated in vitro. IL-2-induced lymphokine-activated killer (LAK) cells were prepared from 38 MDS patients and 20 normal subjects. The cytotoxicity of LAK cells against K562 and Raji cell lines and MDS blasts was significantly reduced in high-risk MDS (refractory anaemia with excess blasts (RAEB), RAEB in transformation, and leukaemic transformation of MDS), but was relatively well-preserved in low-risk MDS (refractory anaemia (RA) and RA with ringed sideroblasts). Examination of the immunophenotypes of freshly-isolated lymphocytes showed that the percentage of CD4+ cells in low- risk MDS and the percentage of CD3+, CD4+ and CD8+ cell populations in high- risk MDS was significantly reduced compared with these populations in normal subjects. After cultivation with IL-2, these three cell populations were still reduced in the corresponding MDS groups and the percentage of CD3- CD56+ cells were significantly reduced in high-risk MDS. There was a positive correlation between the percentage of K562 cells lysed by MDS LAK cells and the percentage of CD3-CD56+ lymphocytes in MDS LAK cells. These aberrant lymphocyte subpopulations appeared to explain, at least in part, the reduced LAK cell cytotoxicity in MDS. These results present a possibility that IL-2 and LAK therapies are ineffective for most high-risk MDS patients, whereas they have potential value for low-risk MDS patients whose lymphocyte cytotoxicity is usually preserved.

    DOI： 10.1111/j.1365-2141.1994.tb04787.x

    Web of Science

    Scopus

    PubMed

    researchmap

  • A novel megakaryocyte potentiator produced by MC-1 human lung cancer cell line 査読

    Shin Ichiro Kuriya, Kiyoyuki Ogaia, Emi Ari, Hiroyuki Hamaguchi, Norio Yokose, Yukie Anzai, Takeo Nomura

    Pathobiology   61 ( 5-6 )   256 - 267   1993年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：KARGER  

    The hematopoietic stimulating activity of a human lung cancer cell line, MC-1, was investigated. The protein fraction (MC-1 protein) was prepared from the serum-free culture supernatant of MC-1 cells using hydroxyapatite and concanavalin A-agarose columns. In serum-containing cultures, MC-1 protein stimulated colony formation by megakaryocyte colony-forming units (CFU), erythroid burst-forming units and granulocyte/macrophage (GM) CFU. The stimulating effect was strongest for megakaryocyte CFU. The factor having megakaryocyte colony-stimulating activity was shown to be a protein whose molecular weight was determined to be 23, 000 daltons by gel filtration. By various analyses, this protein was shown to be molecularly different from the heretofore-identified cytokines that may affect megakaryocytopoiesis, i.e., interleukin-1 (IL-1), IL-2, IL-3. IL-6, IL-7, IL-11, granulocyte colony-stimulating factor (CSF), macrophage CSF, GM-CSF, leukemia inhibitory factor, stem cell factor and tumor necrosis factor. Under serum-free conditions, MC-1 protein augmented murine megakaryocyte colony formation in the presence of murine IL-3 and increased the acetylcholinesterase activity of purified murine megakaryocytes. It was also shown that MC-1 protein stimulated human megakaryocyte colony formation. It was concluded that MC-1 cells produce a megakaryocyte potentiator which is molecularly different from any heretofore-identified cytokines. © 1993 S. Karger AG, Basel.

    DOI： 10.1159/000163804

    Web of Science

    Scopus

    PubMed

    researchmap

▼全件表示

書籍等出版物

  • 血液疾患 消化器内視鏡所見を中心に （共著）

    臓器相関 胃粘膜病変の基礎と臨床 ライフサイエンス出版  1994年 

    　詳細を見る

MISC

  • Picture in Clinical Hematology(No.110) S状結腸がん術後に発症し急性増悪を来した非白血性皮膚白血病

    由井 俊輔, 藤原 裕介, 横瀬 紀夫, 猪口 孝一

    臨床血液   59 ( 2 )   135 - 135   2018年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • Picture in Clinical Hematology No. 110

    由井俊輔, 藤原裕介, 横瀬紀夫, 猪口孝一

    臨床血液   59 ( 2 )   135(J‐STAGE)   2018年

    　詳細を見る

    記述言語：日本語  

    DOI： 10.11406/rinketsu.59.135

    J-GLOBAL

    researchmap

  • Picture in Clinical Hematology No. 110

    由井 俊輔, 藤原 裕介, 横瀬 紀夫, 猪口 孝一

    臨床血液   59 ( 2 )   135 - 135   2018年

    　詳細を見る

    記述言語：日本語   出版者・発行元：一般社団法人 日本血液学会  

    DOI： 10.11406/rinketsu.59.135

    researchmap

  • FUNCTIONAL EXPRESSION OF TIM-3 AND CLINICAL SIGNIFICANCE OF PLASMA GALECTIN-9 LEVELS IN MYELODYSPLASTIC SYNDROMES

    T. Asayama, M. Ishibashi, H. Tamura, Y. Kuribayashi-Hamada, N. Takada-Okuyama, A. Onodera-Kondo, K. Moriya, N. Yokose, K. Inokuchi

    HAEMATOLOGICA   102   482 - 482   2017年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • 前立腺肥大として発症し診断に苦慮した小型B細胞リンパ腫の1例

    瀬理祥, 藤原裕介, 由井俊輔, 横瀬紀夫, 猪口孝一

    臨床血液   57 ( 6 )   783(J‐STAGE) - 783   2016年6月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • びまん性大細胞型B細胞リンパ腫患者における新規国際予後指標NCCN-IPIの有用性の検討

    山田 晃子, 田村 秀人, 朝山 敏夫, 守屋 慶一, 奥山 奈美子, 小野寺 麻加, 濱田 泰子, 石橋 真理子, 横瀬 紀夫, 田野崎 栄, 猪口 孝一

    臨床血液   56 ( 7 )   915 - 918   2015年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    び漫性大細胞型B細胞リンパ腫(DLBCL)患者における新規国際予後指標NCCN-IPIの有用性について検討した。DLBCL 188例を対象とした。低、低中間、高中間、高リスク群の5年生存率は、NCCN-IPIでは、それぞれ90.0%、75.7%、63.5%、34.3%、従来のIPIでは、それぞれ83.8%、65.2%、62.5%、41.1%で、NCCN-IPIでは中間群の層別化、より予後不良な高リスク群の同定に優れていた。新規予後指標NMS-IPIを考案して解析した。75歳以上の20例が低中間から低リスク、36例の高中間が低中間リスク、27例が高から高中間リスクに再分類され、低リスク群が10例から30例に増加、高リスク群が42例から15例に減少し、低、低中間、高中間、高リスク群の5年生存率は、それぞれ、92.9%、70.7%、46.5%、29.3%となり、層別化がさらに明確となった。

    DOI： 10.11406/rinketsu.56.915

    researchmap

  • 本邦びまん性大細胞型B細胞性リンパ腫患者における新規国際予後指標NCCN‐IPIの有用性についての検討

    田村秀人, 山田晃子, 守屋慶一, 朝山敏夫, 石橋真理子, 奥山奈美子, 小野寺麻加, 横瀬紀夫, 田野崎栄, 猪口孝一

    日本内科学会雑誌   104 ( Suppl. )   271 - 271   2015年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本内科学会  

    J-GLOBAL

    researchmap

  • 橋本病に合併した甲状腺原発悪性リンパ腫における臨床的特徴とA20遺伝子変異の関与

    浜田泰子, 石橋真理子, 田村秀人, 奥山奈美子, 守屋慶一, 五十嵐健人, 小野瀬裕之, 横瀬紀夫, 五味聖二, 猪口孝一

    日本内科学会雑誌   104 ( Suppl. )   226 - 226   2015年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本内科学会  

    J-GLOBAL

    researchmap

  • 私のこの一枚(113)芽球形質細胞様樹状細胞腫瘍

    横瀬紀夫, 猪口孝一

    血液フロンティア   23 ( 11 )   1519 - 1522   2013年10月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 私のこの一枚 芽球形質細胞様樹状細胞腫瘍

    横瀬 紀夫, 猪口 孝一

    血液フロンティア   23 ( 11 )   1519 - 1522   2013年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

    researchmap

  • マクログロブリン血症を伴うCCND1陰性マントル細胞リンパ腫(MCL)の1例

    岡部雅弘, 横瀬紀夫, 猪口孝一

    臨床血液   53 ( 12 )   2050 - 2051   2012年12月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma 国際誌

    Tsuneaki Hirakawa, Hiroki Yamaguchi, Norio Yokose, Seiji Gomi, Koiti Inokuchi, Kazuo Dan

    Annals of Hematology   89 ( 9 )   897 - 904   2010年9月

    　詳細を見る

    記述言語：英語   出版者・発行元：SPRINGER  

    CHOP-like regimen combined with rituximab is a standard chemotherapy for diffuse large B-cell lymphoma (DLBCL). The relative dose intensity (RDI) was proposed as an index of the dose and administration interval of agents. Previous studies reported that the maintenance of the RDI during CHOP therapy improved the treatment results. However, few studies regarding RDI have reviewed patients receiving combination therapy with CHOP and rituximab. We investigated the influence of RDI maintenance, involving combination therapy with rituximab, on therapeutic effects in patients with DLBCL. We retrospectively examined 152 DLBCL patients who were treated with CHOP-like regimen combined with rituximab in whom the RDI could be followed up. Multivariate analysis revealed that international prognosis index (IPI) high intermediate-high (HI-H) (p=0.005) and RDI of less than 70% (p=0.007) were independent prognostic factors for low progression free survival. Concerning overall survival, IPI HI-H (p=0.027) and an RDI of less than 70% (p=0.002) were involved in an unfavorable prognosis. In addition, age over 60 years (p=0.003), R-THPCOP (p=0.034), or the presence of febrile neutropenia (p=0.004) made RDI maintenance difficult, and prophylactic G-CSF therapy (p=0.026) was useful for maintaining the RDI. Maintaining the RDI is important even in the era of rituximab-combined chemotherapy for DLBCL. © 2010 Springer-Verlag.

    DOI： 10.1007/s00277-010-0956-7

    Web of Science

    Scopus

    PubMed

    researchmap

  • Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes 国際誌

    Hideto Tamura, Kazuo Dan, Norio Yokose, Rika Iwakiri, Masatsugu Ohta, Hisashi Sakamaki, Kaoru Tohyama, Asaka Kondo, Hideya Hyodo, Kyoko Nakamura, Taishi Yamashita, Olga A. Elisseeva, Yoshihiro Oka, Yusuke Oji, Haruo Sugiyama, Kiyoyuki Ogata

    Leukemia Research   34 ( 8 )   986 - 990   2010年8月

    　詳細を見る

    記述言語：英語   出版者・発行元：PERGAMON-ELSEVIER SCIENCE LTD  

    Wilms tumor gene (WT1) mRNA expression in peripheral blood cells was examined in 80 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) transformed from MDS. Serum anti-WT1 antibody titers were also determined in 45 patients. Their long-term follow-up showed that the survival rate became worse as the WT1 mRNA level increased. In particular, a high WT1 mRNA level was a strong predictor of a short time to AML transformation even if adjusted by the International Prognostic Scoring System category. Moreover, high values of anti-WT1 antibody were an independent predictor of longer survival. These data may justify therapeutic strategies targeting WT1 molecules in MDS. © 2009 Elsevier Ltd.

    DOI： 10.1016/j.leukres.2009.11.029

    Web of Science

    Scopus

    PubMed

    researchmap

  • 造血器腫瘍とCD抗原 急性骨髄性白血病の分類とCD抗原

    横瀬紀夫, 猪口孝一

    月刊血液・腫よう科   59 ( 6 )   619 - 624   2009年12月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(有)科学評論社  

    J-GLOBAL

    researchmap

  • 急性骨髄性白血病の分類とCD抗原 (特集 造血器腫瘍とCD抗原)

    横瀬 紀夫, 猪口 孝一

    血液・腫瘍科   59 ( 6 )   619 - 624   2009年12月

    　詳細を見る

    記述言語：日本語   出版者・発行元：科学評論社  

    CiNii Books

    researchmap

  • Blastic plasmacytoid dendritic cell neoplasmの腫瘍細胞の特徴:表面形質の変化および電顕所見

    横瀬紀夫, 大秋美治, 平川経晃, 檀和夫, 猪口孝一

    臨床血液   50 ( 9 )   1120 - 1120   2009年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 骨髄異形成症候群における末梢血WT1 mRNA発現と抗WT1抗体産生の臨床的意義

    田村秀人, 緒方清行, 横瀬紀夫, 岩切理歌, 大田雅嗣, 坂巻壽, 通山薫, 山下泰史, 近藤麻加, 兵働英也, 中村恭子, 尾路祐介, 杉山治夫, 檀和夫

    臨床血液   50 ( 9 )   948 - 948   2009年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 遺伝子転座を伴う胃MALTリンパ腫の一例

    貝津俊英, 横瀬紀夫, 猪口孝一, 宮下次廣, 菅沼一男, 高岡愼市, 岡田進

    日本放射線腫よう学会誌   21 ( Supplement 1 )   207   2009年8月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib 国際誌

    Norio Yokose, Tsuneaki Hirakawa, Koiti Inokuchi

    Leukemia Research   33 ( 8 )   e106   2009年8月

    　詳細を見る

    記述言語：英語   掲載種別：速報，短報，研究ノート等（学術雑誌）  

    DOI： 10.1016/j.leukres.2009.02.021

    Scopus

    PubMed

    researchmap

  • Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: A prospective validation study 国際誌

    Kiyoyuki Ogata, Matteo G. Della Porta, Luca Malcovati, Cristina Picone, Norio Yokose, Akira Matsuda, Taishi Yamashita, Hideto Tamura, Junichi Tsukada, Kazuo Dan

    Haematologica   94 ( 8 )   1066 - 1074   2009年8月

    　詳細を見る

    記述言語：英語   出版者・発行元：FERRATA STORTI FOUNDATION  

    Background: The diagnosis of myelodysplastic syndromes is not always straightforward when patients lack specific diagnostic markers, such as blast excess, karyotype abnormality, and ringed sideroblasts. Design and Methods: We designed a flow cytometry protocol applicable in many laboratories and verified its diagnostic utility in patients without those diagnostic markers. The cardinal parameters, analyzable from one cell aliquot, were myeloblasts (%), B-cell progenitors (%), myeloblast CD45 expression, and channel number of side scatter where the maximum number of granulocytes occurs. The adjunctive parameters were CD11b, CD15, and CD56 expression (%) on myeloblasts. Marrow samples from 106 control patients with cytopenia and 134 low-grade myelodysplastic syndromes patients, including 81 lacking both ringed sideroblasts and cytogenetic aberrations, were prospectively analyzed in Japan and Italy. Results: Data outside the predetermined reference range in 2 or more parameters (multiple abnormalities) were common in myelodysplastic syndromes patients. In those lacking ringed sideroblasts and cytogenetic aberrations, multiple abnormalities were observed in 8/26 Japanese (30.8%) and 37/55 Italians (67.3%) when the cardinal parameters alone were considered, and in 17/26 Japanese (65.4%) and 42/47 Italians (89.4%) when all parameters were taken into account. Multiple abnormalities were rare in controls. When data from all parameters were used, the diagnostic sensitivities were 65% and 89%, specificities were 98% and 90%, and likelihood ratios were 28.1 and 8.5 for the Japanese and Italian cohorts, respectively. Conclusions: This protocol can be used in the diagnostic work-up of low-grade myelodysplastic syndromes patients who lack specific diagnostic markers, although further improvement in diagnostic power is desirable. ©2009 Ferrata Storti Foundation.

    DOI： 10.3324/haematol.2009.008532

    Web of Science

    Scopus

    PubMed

    researchmap

  • P036 Diagnostic utility of flow cytometry in myelodysplastic syndromes lacking conventional diagnostic markers: a prospective validation study

    K. Ogata, M. Della Porta, L. Malcovati, C. Picone, N. Yokose, A. Matsuda, T. Yamashita, H. Tamura, J. Tsukada, K. Dan, M. Cazzola

    Leukemia Research   33 ( SUPPL. 1 )   S79 - S79   2009年5月

    　詳細を見る

    記述言語：英語   出版者・発行元：PERGAMON-ELSEVIER SCIENCE LTD  

    DOI： 10.1016/S0145-2126(09)70116-X

    Web of Science

    Scopus

    researchmap

  • P048 Clinical significance of WT1mRNA expression and anti-WT1 antibodies in peripheral blood from myelodsplastic syndrome patients

    H. Tamura, K. Dan, N. Yokose, R. Iwakiri, M. Ohta, H. Sakamaki, K. Tohyama, A. Kondo, K. Nakamura, T. Yamashita, T. Tsuji, H. Sigiyama, K. Ogata

    Leukemia Research   33 ( SUPPL. 1 )   S86 - S86   2009年5月

    　詳細を見る

    記述言語：英語   出版者・発行元：PERGAMON-ELSEVIER SCIENCE LTD  

    DOI： 10.1016/S0145-2126(09)70128-6

    Web of Science

    Scopus

    researchmap

  • 大量心嚢液を認めた Primary effusion lymphoma (PEL)

    平川 経晃, 横瀬 紀夫, 檀 和夫, 猪口 孝一

    臨床血液   50 ( 4 )   215 - 215   2009年4月

    　詳細を見る

    記述言語：日本語  

    CiNii Books

    researchmap

  • Picture in Clinical Hematology(No.36) 大量心嚢液を認めたPrimary effusion lymphoma(PEL)

    平川 経晃, 横瀬 紀夫, 檀 和夫, 猪口 孝一

    臨床血液   50 ( 4 )   215 - 215   2009年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 骨髄異形成症候群における末梢血WT1mRNA測定の有用性

    田村秀人, 緒方清行, 横瀬紀夫, 岩切理歌, 大田雅嗣, 坂巻壽, 通山薫, 近藤麻加, 中村恭子, 檀和夫

    日本内科学会雑誌   98 ( Suppl. )   153 - 153   2009年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本内科学会  

    J-GLOBAL

    researchmap

  • Protein-losing gastroenteropathy: Unusual presentation of multiple myeloma 国際誌

    Norio Yokose, Yoshiharu Ohaki, Teppei Fujino, Norio Itokawa, Kazuo Dan, Koiti Inokuchi

    Annals of Hematology   88 ( 7 )   705 - 707   2009年

    　詳細を見る

    記述言語：英語   掲載種別：速報，短報，研究ノート等（学術雑誌）   出版者・発行元：SPRINGER  

    DOI： 10.1007/s00277-008-0655-9

    Web of Science

    Scopus

    PubMed

    researchmap

  • Picture in Clinical Hematology No. 36

    平川 経晃, 横瀬 紀夫, 檀 和夫, 猪口 孝一

    臨床血液   50 ( 4 )   215 - 215   2009年

    　詳細を見る

    記述言語：日本語   出版者・発行元：一般社団法人 日本血液学会  

    researchmap

  • 急性骨髄性白血病の分類とCD抗原

    横瀬紀夫, 猪口孝一

    血液・腫瘍科   59 ( 6 )   619 - 624   2009年

    　詳細を見る

  • びまん性大細胞性B細胞リンパ腫に関してCHOP like regimenにおけるRDIの維持と治療効果の後方視的解析

    平川経晃, 山口博樹, 横瀬紀夫, 五味聖二, 猪口孝一, 檀和夫

    臨床血液   49 ( 9 )   863 - 863   2008年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 肺葉切除術とリポソーマルアムホテリシンB投与により治療に成功し得た急性骨髄性白血病症例の肺接合菌症

    横瀬紀夫, 大秋美治, 脇田知志, 糸川典夫, 猪口孝一

    臨床血液   49 ( 9 )   1058 - 1058   2008年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 骨髄異形成症候群における末梢血WT‐1 mRNAの臨床的意義

    田村秀人, 緒方清行, 横瀬紀夫, 岩切理歌, 大田雅嗣, 坂巻壽, 通山薫, 山下泰史, 近藤麻加, 守屋慶一, 兵働英也, 塩井由美子, 中村恭子, 檀和夫

    臨床血液   49 ( 9 )   868 - 868   2008年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 68) 広汎なST上昇と徐脈性不整脈を合併した後腹膜線維症の稀有な1例(第206回日本循環器学会関東甲信越地方会)

    林 洋史, 稲見 茂信, 横瀬 紀夫, 大秋 美治, 山本 真功, 白壁 章宏, 村上 大介, 田近 研一郎, 淀川 顕司, 徳山 権一, 高野 雅充, 清宮 康嗣, 大野 則彦, 大場 崇芳, 雪吹 周生, 清野 精彦

    Circulation journal : official journal of the Japanese Circulation Society   72 ( 0 )   945 - 945   2008年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：社団法人日本循環器学会  

    CiNii Books

    researchmap

  • 68) 広汎なST上昇と徐脈性不整脈を合併した後腹膜線維症の稀有な1例(第206回日本循環器学会関東甲信越地方会)

    林 洋史, 稲見 茂信, 横瀬 紀夫, 大秋 美治, 山本 真功, 白壁 章宏, 村上 大介, 田近 研一郎, 淀川 顕司, 徳山 権一, 高野 雅充, 清宮 康嗣, 大野 則彦, 大場 崇芳, 雪吹 周生, 清野 精彦

    Circulation journal : official journal of the Japanese Circulation Society   72 ( Supplement 2 )   945 - 945   2008年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：社団法人日本循環器学会  

    CiNii Books

    J-GLOBAL

    researchmap

  • Increased apoptosis of circulating T cells in myelodysplastic syndromes 国際誌

    Yumiko Shioi, Hideto Tamura, Norio Yokose, Chikako Satoh, Kazuo Dan, Kiyoyuki Ogata

    Leukemia Research   31 ( 12 )   1641 - 1648   2007年12月

    　詳細を見る

    記述言語：英語   出版者・発行元：PERGAMON-ELSEVIER SCIENCE LTD  

    The mechanism of T cell lymphopenia in myelodysplastic syndromes (MDS) is unknown. We investigated apoptosis in freshly isolated and cultured lymphocytes; the latter were used to detect cells not yet apoptotic but destined for apoptosis. Apoptosis increased in both fresh and cultured T cells in MDS compared with those from healthy controls. Furthermore, in lymphopenic MDS patients the lymphocyte count correlated negatively with the degree of T cell apoptosis. MDS T cells showed increased Fas expression. However, in MDS but not in controls, the degree of T cell apoptosis was independent of the Fas expression level, and exogenous anti-Fas antibodies did not modulate T cell apoptosis. Mechanisms other than the Fas-Fas ligand pathway may induce T cell apoptosis in MDS. © 2007 Elsevier Ltd. All rights reserved.

    DOI： 10.1016/j.leukres.2007.03.026

    Web of Science

    Scopus

    PubMed

    researchmap

  • 免疫学的機序によると思われる蛋白漏出性胃腸症を合併したsymptomatic myeloma

    横瀬紀夫, 藤野鉄平, 糸川典夫, 大秋美治, 檀和夫

    臨床血液   48 ( 9 )   1138 - 1138   2007年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 完全房室ブロック発症直後に最未分化型急性骨髄性白血病を発症し,寛解後突然死した透析患者の1剖検例

    糸川典夫, 横瀬紀夫, 徳山権一, 檀和夫, 大秋美治

    臨床血液   48 ( 9 )   1036 - 1036   2007年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Increased apoptosis of circulating T cells in myelodysplastic syndromes

    C. Satoh, Y. Shioi, H. Tamura, N. Yokose, K. Dan, K. Ogata

    LEUKEMIA RESEARCH   31   S66 - S66   2007年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：PERGAMON-ELSEVIER SCIENCE LTD  

    Web of Science

    researchmap

  • Pasteurella multocida sepsis, due to a scratch from a pet cat, in a post-chemotherapy neutropenic patient with non-Hodgkin lymphoma

    Norio Yokose, Kazuo Dan

    International Journal of Hematology   85 ( 2 )   146 - 148   2007年2月

    　詳細を見る

    記述言語：英語   出版者・発行元：CARDEN JENNINGS PUBL CO LTD  

    Pasteurella (P) multocida exists in a variety of animals and causes diverse infections in humans due to animal bites and scratches, usually by cats or dogs, and oral and respiratory infection. We report a case of P multocida sepsis due to a scratch from a pet cat, complicated with disseminated intravascular coagulation in a post-chemotherapy neutropenic patient with non-Hodgkin lymphoma. The patient was a febrile 79-year-old woman with disturbed consciousness and subcutaneous abscess in her right hand due to a scratch from a pet cat. She was successfully treated with empirical antibiotic therapy with cefepime and administrations of granulocyte colony-stimulating factor and danaparoid. The minimum inhibitory concentration of cefepime against the isolate from this case was <2mg/L. Although a few days are required before a diagnosis of P multocida infection can be made from a bacteriological study, the infection can be successfully treated against febrile neutropenia with empirical cefepime. In a literature review, 7 cases, including ours, with hematological malignancies complicated with P multocida infection were identified and we summarized the clinical characteristics of these cases. These cases demonstrate the importance of the prevention of close contact between pet animals and immunocompromised hosts such as post-chemotherapy neutropenic patients. © 2007 The Japanese Society of Hematology.

    DOI： 10.1532/IJH97.06176

    Web of Science

    Scopus

    PubMed

    researchmap

  • Two cases of subacute combined degeneration: Magnetic resonance findings

    Susumu Okada, Tomoyuki Kuwako, Hidenobu Nakajo, Makiko Ishihara, Fumio Uchiyama, Rinnosuke Obo, Norio Yokose, Makoto Hamamoto

    Journal of Nippon Medical School   73 ( 6 )   328 - 331   2006年12月

    　詳細を見る

    記述言語：英語  

    We report two cases of subacute combined degeneration. Both patients had undergone total gastrectomy. The chief complaints were numbness in both upper extremities in case 1 and numbness in both the upper and lower extremities and gait disturbance in case 2. The pain, temperature, and vibration senses of both patients were decreased. Laboratory examinations showed macrocytic anemia and a decreased serum vitamin B12 level in both cases. In both cases T2-weighted magnetic resonance images showed an area of hyperintensity in the dorsal columns of the cervical spinal cord. The patients were treated with vitamin B12. The abnormal signals had disappeared on follow-up magnetic resonance examination 1 year later in case 1 and 3 months later in case 2. These patients showed neurological improvement, but the numbness in the upper extremities persisted even after the area of abnormal signal intensity had disappeared in case 1.

    DOI： 10.1272/jnms.73.328

    Scopus

    PubMed

    researchmap

  • 末血で染色体異常を認めclonalな増殖が疑われるT細胞増多症を伴ったT‐cell rich B‐cell lymphoma(TCRLBCL)

    横瀬紀夫, 大秋美治, 檀和夫

    臨床血液   47 ( 9 )   1266 - 1266   2006年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-) [9] 国際誌

    Norio Yokose, Yumiko Shioi, Yuich Sugisaki, Yoshiharu Ohaki, Kiyoyuki Ogata, Kazuo Dan

    Leukemia and Lymphoma   47 ( 7 )   1415 - 1417   2006年7月

    　詳細を見る

    記述言語：英語   掲載種別：速報，短報，研究ノート等（学術雑誌）   出版者・発行元：TAYLOR & FRANCIS LTD  

    DOI： 10.1080/10428190600581625

    Web of Science

    Scopus

    PubMed

    researchmap

  • 92)4弁の疣贅と疣贅を通過する複数の左右短絡を認めた感染性心内膜炎の一例(第197回日本循環器学会関東甲信越地方会)

    田近 研一郎, 西條 由之, 安藤 友一, 秋谷 麻衣, 山本 真功, 木股 仲恒, 富田 和憲, 村上 大介, 小川 紅, 徳山 権一, 稲見 茂信, 高野 雅充, 清宮 康嗣, 大場 崇芳, 川口 直美, 野村 敦宣, 奥村 敏, 水野 杏一, 横瀬 紀夫, 新井 悟, 大秋 美治

    Circulation journal : official journal of the Japanese Circulation Society   70 ( Supplement 2 )   1030 - 1030   2006年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：社団法人日本循環器学会  

    CiNii Books

    J-GLOBAL

    researchmap

  • 92)4弁の疣贅と疣贅を通過する複数の左右短絡を認めた感染性心内膜炎の一例(第197回日本循環器学会関東甲信越地方会)

    田近 研一郎, 西條 由之, 安藤 友一, 秋谷 麻衣, 山本 真功, 木股 仲恒, 富田 和憲, 村上 大介, 小川 紅, 徳山 権一, 稲見 茂信, 高野 雅充, 清宮 康嗣, 大場 崇芳, 川口 直美, 野村 敦宣, 奥村 敏, 水野 杏一, 横瀬 紀夫, 新井 悟, 大秋 美治

    Circulation journal : official journal of the Japanese Circulation Society   70 ( 0 )   1030 - 1030   2006年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：社団法人日本循環器学会  

    CiNii Books

    researchmap

  • 細胞内CD20陽性・細胞表面CD20陰性を示したCD5陽性びまん性大細胞型B細胞リンパ腫

    横瀬 紀夫, 大秋 美治, 杉崎 祐一, 塩井 由美子, 緒方 清行, 檀 和夫

    日本血液学会・日本臨床血液学会総会プログラム・抄録集   67回・47回   932 - 932   2005年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：日本臨床血液学会  

    researchmap

  • 細胞内CD20陽性・細胞表面CD20陰性を示したCD5陽性びまん性大細胞型B細胞リンパ腫

    横瀬紀夫, 大秋美治, 杉崎祐一, 塩井由美子, 緒方清行, 檀和夫

    臨床血液   46 ( 8 )   932   2005年8月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 当科における真性多血症の臨床検討

    山田 隆, 山口 博樹, 中村 恭子, 田村 秀人, 田野崎 栄, 横瀬 紀夫, 田近 賢二, 緒方 清行, 猪口 孝一, 檀 和夫

    日本血液学会・日本臨床血液学会総会プログラム・抄録集   66回・46回   983 - 983   2004年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：日本臨床血液学会  

    researchmap

  • 当科における真性多血症の臨床検討

    山田隆, 山口博樹, 中村恭子, 田村秀人, 田野崎栄, 横瀬紀夫, 田近賢二, 緒方清行, 猪口孝一

    臨床血液   45 ( 8 )   983   2004年8月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 急性骨髄性白血病(AML)細胞における補助刺激分子B7‐2とB7‐H2(ICOS ligand)の発現と臨床意義

    田村秀人, 横瀬紀夫, 中村恭子, 塩井由美子, 橘美紀子, 兵働英也, 緒方清行, 檀和夫

    日本内科学会雑誌   93 ( Suppl. )   141 - 141   2004年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本内科学会  

    J-GLOBAL

    researchmap

  • Expression and role of B7 family molecules, B7-H1 and B7-H2, in patients with acute myeloid leukemia.

    H Tamura, K Ogata, N Yokose, K Nakamura, Y Shioi, H Hyodo, M Tachibana, HD Dong, SD Wang, LP Chen, KZ Dan

    BLOOD   102 ( 11 )   234B - 234B   2003年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 骨髄異形成症候群(MDS)患者リンパ球のapoptosisに関する検討

    塩井由美子, 横瀬紀夫, 兵働英也, 橘美紀子, 中村恭子, 田村秀人, 緒方清之, 檀和夫

    臨床血液   44 ( 8 )   821 - 821   2003年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 急性骨髄性白血病(AML)細胞における補助刺激分子B7‐H2(ICOS ligand)の発現と予後との関連

    田村秀人, 横瀬紀夫, 中村恭子, 塩井由美子, 橘美紀子, 兵働英也, 緒方清行, 檀和夫

    臨床血液   44 ( 8 )   828 - 828   2003年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • メルカゾールによる再生不良性貧血

    福田健, 田中由理子, 石井新哉, 田村秀樹, 亀谷純, 岡島史宜, 城所葉, 横瀬紀夫, 及川真一

    日本内分泌学会雑誌   79   90 - 90   2003年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本内分泌学会  

    J-GLOBAL

    researchmap

  • Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome 国際誌

    Kiyoyuki Ogata, Kyoko Nakamura, Norio Yokose, Hideto Tamura, Mikiko Tachibana, Osamu Taniguchi, Rika Iwakiri, Tatsuyuki Hayashi, Hisashi Sakamaki, Yoshiro Murai, Kaoru Tohyama, Shigeru Tomoyasu, Yasunobu Nonaka, Mayumi Mori, Kazuo Dan, Yataro Yoshida

    Blood   100 ( 12 )   3887 - 3896   2002年12月

    　詳細を見る

    記述言語：英語   出版者・発行元：AMER SOC HEMATOLOGY  

    Knowledge of the blast phenotype in myelodysplastic syndrome (MDS) would be valuable, as in other malignancies, but remains sparse. This is mainly because MDS blasts are a minor population in clinical samples, making analysis difficult. Thus, for this blast phenotype study, we prepared blast-rich specimens (using a new density centrifugation reagent for harvesting blasts) from blood and marrow samples of 95 patients with various MDS subtypes and 21 patients with acute leukemia transformed from MDS (AL-MDS). Flow cytometry revealed that a high proportion of the enriched blast cells (EBCs) from almost all patients showed an immunophenotype of committed myeloid precursors (CD34+CD38+HLA-DR+ CD13+CD33+), regardless of the disease subtype. The cytochemical reaction for myeloperoxidase was negative in 58% of the cases. Thus, the EBC phenotype is more immature in MDS than in de novo acute myeloid leukemia. MDS EBCs often co-expressed stem cell antigens and late-stage myeloid antigens asynchronously, but rarely expressed T- and B-lymphoid cell-specific antigens. Markers for myeloid cell maturation (CD10 and CD15) were more prevalent on EBCs from low-risk MDS (refractory anemia [RA] and RA with ringed sideroblasts), whereas markers for myeloid cell immaturity (CD7 and CD117) were more prevalent on EBCs from high-risk MDS (chronic myelomonocytic leukemia, RA with excess blasts [RAEB], and RAEB in transformation) and AL-MDS. A shift to a more immature phenotype of EBCs, accompanying disease progression, was also documented by sequential phenotyping of the same patients. Further, CD7 positivity of EBCs was an independent variable for a poor prognosis in MDS. These data represent new, valuable information regarding MDS. © 2002 by The American Society of Hematology.

    DOI： 10.1182/blood-2002-01-0222

    Web of Science

    Scopus

    PubMed

    researchmap

  • 慢性リンパ性白血病と関連疾患（共著）

    横瀬紀夫, 檀和夫

    臨床検査   46(11), 1231-1233 ( 11 )   1231 - 1233   2002年10月

    　詳細を見る

    記述言語：日本語  

    DOI： 10.11477/mf.1542905221

    J-GLOBAL

    researchmap

  • 【造血器腫瘍】 造血器腫瘍の病態と分類 慢性リンパ性白血病と関連疾患

    横瀬 紀夫, 檀 和夫

    臨床検査   46 ( 11 )   1231 - 1233   2002年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(株)医学書院  

    DOI： 10.11477/mf.1542905221

    researchmap

  • Imatinib mesylateが著効した化学療法抵抗性のdouble Ph染色体陽性急性混合性白血病の1症例

    竹森 健, 田村 秀人, 猪口 孝一, 水木 太郎, 田近 賢二, 山田 隆, 横瀬 紀夫, 中村 恭子, 中村 弘之, 中山 一隆, 橘 美紀子, 足澤 美樹, 内田 直也, 稲見 光春, 緒方 清行, 檀 和夫

    臨床血液   43 ( 9 )   883 - 883   2002年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 治療抵抗性急性白血病に対しgemtuzumab ozogamicin(Mylotarg)を投与後に同種臍帯血移植を施行した症例

    中山 一隆, 稲見 光春, 横瀬 紀夫, 中村 弘之, 水木 太郎, 橋本 充弘, 内田 直也, 中村 恭子, 緒方 清行, 猪口 孝一, 田近 賢二, 檀 和夫

    臨床血液   43 ( 8 )   386 - 386   2002年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • MDSから移行したdouble Ph陽性急性白血病の1例

    内田 直也, 稲見 光春, 渡辺 綾子, 橘 美紀子, 中山 一隆, 中村 恭子, 横瀬 紀夫, 田近 賢二, 緒方 清行, 猪口 孝一, 檀 和夫

    臨床血液   43 ( 8 )   410 - 410   2002年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 悪性リンパ腫患者におけるESHAP/ACES療法及びエトポシド単独投与後のG-CSFによる末梢血幹細胞の動員

    中村 弘之, 内田 直也, 稲見 光春, 橘 美紀子, 足澤 美樹, 橋本 充弘, 塩井 由美子, 水木 太郎, 中山 一隆, 中村 恭子, 田村 秀人, 横瀬 紀夫, 田近 賢二, 猪口 孝一, 緒方 清行, 檀 和夫

    臨床血液   43 ( 8 )   358 - 358   2002年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • G-CSF産生Hodgkinリンパ腫

    守屋 慶一, 横瀬 紀夫, 中山 一隆, 田近 賢二, 緒方 清行, 猪口 孝一, 檀 和夫

    臨床血液   43 ( 8 )   361 - 361   2002年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 骨髄異形成症候群(MDS)における芽球形質の臨床的意義 新規芽球分離試薬を用いた解析

    緒方 清行, 中村 恭子, 横瀬 紀夫, 田村 秀人, 橘 美紀子, 谷口 脩, 岩切 理歌, 林 達之, 坂巻 壽, 村井 善郎, 通山 薫, 友安 茂, 野中 泰延, 森 眞由美, 檀 和夫, 吉田 彌太郎

    臨床血液   43 ( 8 )   224 - 224   2002年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • der(14)t(11;14)(q13;q32)を有するT細胞性悪性リンパ腫

    横瀬 紀夫, 中山 一隆, 稲見 光春, 橘 美紀子, 田村 秀人, 中村 恭子, 山田 隆, 田近 賢二, 猪口 孝一, 緒方 清行, 杉崎 祐一, 檀 和夫

    臨床血液   43 ( 8 )   365 - 365   2002年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 全身性エリテマトーデスの経過中に発症した胃悪性リンパ腫の1例

    津久井拓, 鈴木健司, 平塚哲郎, 辰口篤志, 横瀬紀夫, 三宅一昌, 吉野槙一, 坂本長逸

    モダンフィジシャン   22 ( 6 )   795 - 798   2002年6月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 【胃のMALTリンパ腫】 全身性エリテマトーデスの経過中に発症した胃悪性リンパ腫の1例

    津久井 拓, 鈴木 健司, 平塚 哲郎, 辰口 篤志, 横瀬 紀夫, 三宅 一昌, 吉野 槙一, 坂本 長逸

    Modern Physician   22 ( 6 )   795 - 798   2002年6月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(株)新興医学出版社  

    52歳男.主訴はタール便,上腹部不快感.右上下肢の不全麻痺と深部反射の亢進が認められた.諸検査結果から胃悪性リンパ腫と診断し,H.pyloriの除菌療法を行った.しかし胃内視鏡所見に改善なく,腹部CT検査により腹腔内リンパ節の増大を認めた為,CHOP療法を開始した.sIL-2値の低下を認め,心窩部痛が出現した為,急性膵炎と診断し,メシル酸ガベキセートの点滴投与を行った.血清アミラーゼ値は126IU/lと改善したが,腹部CT検査で膵周囲に多数のリンパ節腫脹とリンパ節による膵の圧排像,大動脈周囲のリンパ節腫脹を認めた為,ESHAP療法を開始した.しかし治療効果が認められず,中等量のAraC療法を開始したが,急性腎不全,鬱血性腎不全を合併し,治療を行うも死亡した

    researchmap

  • 血栓性血小板減少性紫斑病(TTP)にネフローゼ症候群を合併し,副腎皮質ステロイドが著効した1例

    水木太郎, 植木伸江, 中村弘之, 中山一隆, 横瀬紀夫, 田近賢二, 猪口孝一, 緒方清行, 檀和夫

    臨床血液   43 ( 1 )   55 - 55   2002年1月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Determination of phenotypic features of blasts from patients with myelodysplastic syndrome (MDS): Analyses of blasts harvested by a new method.

    K Ogata, K Nakamura, N Yokose, K Dan, H Sakamaki, K Tohyama, M Mori, Y Murai, T Hayashi, Y Nonaka, S Tomoyasu, Y Yoshida

    BLOOD   98 ( 11 )   620A - 620A   2001年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Ph陰性bcr/abl陰性(Ph‐/bcr‐)CML3症例とPh‐/bcr+CML2症例の臨床的検討

    植木信江, 水木太郎, 中山一隆, 中村弘之, 足沢美樹, 山口博樹, 横瀬紀夫, 田近賢二, 檀和夫

    臨床血液   42 ( 10 )   964 - 964   2001年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 当科で経験した難治性B‐Cellリンパ腫10症例に対するRituximabの効果

    田近賢二, 橋本充宏, 橘美紀子, 塩井由美子, 水木太郎, 中山一隆, 中村弘之, 横瀬紀夫, 壇和夫

    臨床血液   42 ( 10 )   403 - 1010   2001年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 白血病クローンとは異なる染色体異常が長期間続いている寛解持続中の急性骨髄性白血病症例

    兵働英也, 横瀬紀夫, 中山一隆, 中村弘之, 中村恭子, 田辺賢二, 猪口孝一, 緒方清行, 壇和夫

    臨床血液   42 ( 7 )   577   2001年7月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 白血病クローンとは異なる染色体異常が長期間続いている緩解持続中の急性骨髄性白血病症例

    兵働 英也, 横瀬 紀夫, 中山 一隆, 中村 弘之, 中村 恭子, 田辺 賢二, 猪口 孝一, 緒方 清行, 檀 和夫

    臨床血液   42 ( 7 )   577 - 577   2001年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 8;21転座を有する急性骨髄性白血病の臨床的検討(Clinical Study of Acute Myeloid Leukemia with t(8;21))

    横瀬 紀夫, 塩井 由美子, 安 恵美, 緒方 清行, 檀 和夫, 石田 陽治, 厨 信一郎, 坂巻 壽, 矢ヶ崎 史治, 別所 正美

    International Journal of Hematology   73 ( Suppl.1 )   49 - 49   2001年3月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • 免疫染色によるlung resistance proteins(LRP)検出法の検討(Evaluation of immunocytochemical method to detect lung resistance proteins)

    兵働 英也, 橘 美紀子, 塩井 由美子, 中村 恭子, 横瀬 紀夫, 緒方 清行, 檀 和夫

    International Journal of Hematology   73 ( Suppl.1 )   133 - 133   2001年3月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • 8;21転座を有する急性骨髄性白血病の臨床的検討

    横瀬紀夫, 檀和夫, 石田陽治, 厨信一郎, 坂巻寿, 矢ケ崎史治, 別所正美, 浜口裕之, 富山順治

    Int J Hematol Suppl   73 ( Supplement 1 )   49   2001年3月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • 免疫染色によるlung resistance proteins(LRP)検出法の検討

    兵働英也, 橘美紀子, 塩井由美子, 中村恭子, 横瀬紀夫, 緒方清行, 檀和夫

    Int J Hematol Suppl   73 ( Supplement 1 )   133   2001年3月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia

    K. Ogata, N. Yokose, Y. Shioi, Y. Ishida, J. Tomiyama, H. Hamaguchi, F. Yagasaki, M. Bessyo, H. Sakamaki, K. Dan, S. Kuriya

    British Journal of Haematology   115 ( 3 )   612 - 615   2001年

    　詳細を見る

    記述言語：英語   出版者・発行元：BLACKWELL PUBLISHING LTD  

    Debate exists over whether CD7 expression indicates an unfavourable prognosis in de novo acute myeloid leukaemia (AML). Meanwhile, the type of cytogenetics is a strong prognostic factor in AML. We analysed 256 de novo adult AML cases and found that the proportion of CD7+ cases increased stepwise from the cases with favourable cytogenetics to the cases with intermediate and unfavourable cytogenetics (3 out of 69 cases, 51 out of 140 cases and 25 out of 47 cases respectively, P < 0.0001). CD7-positivity adversely affected the survival only in the cases with unfavourable cytogenetics (P < 0.03). We recommend that CD7 expression in AML be interpreted in association with the cytogenetics.

    DOI： 10.1046/j.1365-2141.2001.03139.x

    Web of Science

    Scopus

    PubMed

    researchmap

  • Association between natural killer cell activity and infection in immunologically normal elderly people

    K. Ogata, E. An, Y. Shioi, K. Nakamura, S. Luo, N. Yokose, S. Minami, K. Dan

    Clinical and Experimental Immunology   124 ( 3 )   392 - 397   2001年

    　詳細を見る

    記述言語：英語  

    Congenital patients who lack natural killer (NK) cell activity experience repeated polymicrobial infections. NK cell activity varies significantly among normal people, but it is unknown whether this variation influences their ability to fight infections. This study examined this concern. NK cell activity and other variables, i.e. age, sex, performance status (PS), serum albumin value, lymphocyte and neutrophil counts, various lymphocyte subsets, etc. were determined for 108 immunologically normal elderly subjects who were in nursing homes due to an impaired PS. We analysed for correlations between these variables and the follow-up results of the subjects. Forty-eight subjects developed infection(s) during the first year of follow-up. A low NK cell activity was associated with the development of infection (P = 0.0105, multivariate logistic regression analysis). The relative risk for the development of infection increased in accordance with the decrease in the NK cell activity. Eleven subjects died of infection during the study period. A low NK cell activity was associated with short survival due to infection (P = 0.0056, multivariate Cox's proportional-hazards regression analysis). Our data indicate that low NK cell activity is associated with development of infections and death due to infection in immunologically normal elderly subjects with an impaired PS.

    DOI： 10.1046/j.1365-2249.2001.01571.x

    Scopus

    PubMed

    researchmap

  • CD20-positive T cell leukemia/lymphoma: Case report and review of the literature

    N. Yokose, K. Ogata, Y. Sugisaki, S. Mori, T. Yamada, E. An, K. Dan

    Annals of Hematology   80 ( 6 )   372 - 375   2001年

    　詳細を見る

    記述言語：英語  

    We report on a case of CD20-positive peripheral T cell lymphoma. The lymphoma cell was positive for CD20 and T cell lineage markers such as cytoplasmic CD3, CD4, and CD5 and had a monoclonal rearrangement of the T cell receptor (TCR) γ chain gene. The clinical characteristics resembled angioimmunoblastic lymphadenopathy: spontaneous regression of lymphadenopathy and immunological abnormalities such as polyclonal hypergammaglobulinemia, positive results of direct and indirect antiglobulin tests, and a high antinuclear antibody titer. We reviewed seven cases of CD20-positive T cell malignancies including the present case. Three were immature T cell malignancies (acute lymphoblastic leukemia) and four were peripheral T cell malignancies (non-Hodgkin's lymphoma and chronic lymphocytic leukemia). Hepatomegaly and/or splenomegaly were common features. Further cases must be evaluated to understand the clinical significance of the CD20 expression on the surface of T cell malignancies.

    DOI： 10.1007/s002770100297

    Scopus

    PubMed

    researchmap

  • 当科における本態性血小板血症の検討

    山田隆, 田野崎栄, 横瀬紀夫, 田近賢二, 猪口孝一, 緒方清行, 檀和夫

    臨床血液   41 ( 10 )   1039 - 1039   2000年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 急性骨髄性白血病におけるCD7発現と染色体異常との関連 CD7発現の臨床的意義の再検討

    塩井由美子, 横瀬紀夫, 中村恭子, 安恵美, 田近賢二, 山田隆, 坂巻寿, 石田陽治, 厨信一郎

    臨床血液   41 ( 10 )   986 - 986   2000年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • IgG型M蛋白血症を認めた白血化リンパ形質細胞様リンパ腫(LPL)の一例

    横瀬紀夫, 羅善順, 塩井由美子, 中村恭子, 橘美紀子, 兵働英也, 田近賢二, 猪口孝一, 檀和夫

    臨床血液   41 ( 10 )   1080   2000年10月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • IgG型M蛋白血症を認めた白血化リンパ形質細胞様リンパ腫(LPL)の1例

    横瀬 紀夫, 羅 善順, 塩井 由美子, 中村 恭子, 橘 美紀子, 兵働 英也, 田近 賢二, 猪口 孝一, 緒方 清行, 檀 和夫

    臨床血液   41 ( 10 )   1080 - 1080   2000年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 当科における急性リンパ性白血病治療の現況

    水木 太郎, 田近 賢二, 橋本 充弘, 塩井 由美子, 中山 一隆, 中村 弘之, 山口 博樹, 中村 佳代, 中村 恭子, 横瀬 紀夫

    臨床血液   41 ( 10 )   1034 - 1034   2000年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 正常高齢者のナチュラルキラー(NK)細胞活性と感染症の発生・予後との関連 前方追跡調査の結果

    安 恵美, 兵働 英也, 橘 美紀子, 塩井 由美子, 中村 恭子, 羅 善順, 横瀬 紀夫, 猪口 孝一, 緒方 清行, 檀 和夫

    International Journal of Hematology   71 ( Suppl.1 )   129 - 129   2000年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • トロンボポイエチン(TPO)の骨髄異形成症候群(MDS)芽球増殖に対する効果 第2報

    横瀬紀夫, 安恵美, 中村恭子, 塩井由美子, 兵働英也, 橘美紀子, 猪口孝一, 檀和夫, LUO S‐S

    International Journal of Hematology. Supplement   71 ( 1 )   180 - 180   2000年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    J-GLOBAL

    researchmap

  • 当科における非ホジキンリンパ腫治療の現況

    水木 太郎, 田近 賢二, 橋本 充弘, 塩井 由美子, 中山 一隆, 中村 弘之, 山口 博樹, 中村 佳代, 中村 恭子, 横瀬 紀夫

    International Journal of Hematology   71 ( Suppl.1 )   164 - 164   2000年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • 正常高齢者のナシュラルキラー(NK)細胞活性と感染症の発生・予後との関連(前方追跡調査の結果)

    安恵美, 兵働英也, 橘美紀子, 塩井由美子, 中村恭子, 横瀬紀夫, 猪口孝一, 檀和夫, LUO S S

    International Journal of Hematology. Supplement   71 ( 1 )   129   2000年4月

    　詳細を見る

    記述言語：日本語  

    J-GLOBAL

    researchmap

  • Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes

    Shan Shun Luo, Kiyoyuki Ogata, Norio Yokose, Takashi Kato, Dan Kazuo

    Stem Cells   18 ( 2 )   112 - 119   2000年

    　詳細を見る

    記述言語：英語   出版者・発行元：ALPHAMED PRESS  

    Thrombopoietin (TPO), a major cytokine involved in megakaryocytopoiesis/thrombopoiesis, may be effective for treatment of the thrombocytopenia associated with myelodysplastic syndromes (MDS). However, it has been unclear whether TPO stimulates proliferation of MDS blasts, as observed in de novo acute myeloid leukemia. This study examined this concern. When marrow cells from 37 MDS cases were cultured with or without recombinant human PEGylated TPO, TPO increased the blast number (stimulation index ≥1.5) in 9 of 16 high-risk MDS cases (refractory anemia with excess blasts [RAEB] and RAEB in transformation) and 4 of 10 cases with MDS transformed to acute leukemia (MDS-AL), but none of 11 cases with low-risk MDS (RA and RA with ringed sideroblasts). When the cell cycle of cultured cells was determined by three-color flow cytometry, TPO activated the cell cycle of MDS cells (causing a decrease in Go-phase cells) in most of the cases whose blast number increased in response to TPO. Reverse transcriptase-polymerase chain reaction analysis detected TPO receptor messenger RNA in purified blasts from all six cases examined, irrespective of the response of their blasts to TPO in culture. Analysis of the patients' characteristics identified a high-serum lactate dehydrogenase (LDH) value as being associated with blast proliferation in high-risk MDS cases (p = 0.0036). We conclude that TPO stimulates in vitro proliferation of blasts from a fraction of MDS patients. High-risk MDS patients, especially those who have a high-serum LDH value, and MDS-AL patients should be monitored with particular care in clinical trials of TPO for MDS.

    DOI： 10.1634/stemcells.18-2-112

    Web of Science

    Scopus

    PubMed

    researchmap

  • Repeated efficacy of all-trans-retinoic acid in an acute promyelocytic leukemia patient [1]

    Ayako Watanabe, Koiti Inokuchi, Taroh Mizuki, Hiroki Yamaguchi, Norio Yokose, Kazuo Dan

    American Journal of Hematology   65 ( 1 )   87 - 88   2000年

    　詳細を見る

    記述言語：英語   掲載種別：速報，短報，研究ノート等（学術雑誌）   出版者・発行元：WILEY-LISS  

    DOI： 10.1002/1096-8652(200009)65:1<87::AID-AJH18>3.0.CO;2-4

    Web of Science

    Scopus

    PubMed

    researchmap

  • 診断に苦渋し急激な経過をとった表在リンパ節腫脹を伴う非典型的慢性骨髄性白血病と思われる1例

    足沢美樹, 山口博樹, 中村恭子, 横瀬紀夫, 山田隆, 田近賢二, 緒方清行, 猪口孝一, 檀和夫

    臨床血液   40 ( 11 )   1210 - 1210   1999年11月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 当科における急性骨髄性白血病(AML)症例の核型・表面形質と予後との関連について

    塩井 由美子, 横瀬 紀夫, 中村 恭子, 安 恵美, 田近 賢二, 山田 隆, 猪口 孝一, 緒方 清行, 檀 和夫

    臨床血液   40 ( 9 )   1004 - 1004   1999年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 炭酸リチウム投与が有効と思われた低形成性骨髄異形成症候群(MDS)の1例

    横瀬 紀夫, 羅 善順, 塩井 由美子, 中村 恭子, 安 恵美, 猪口 孝一, 緒方 清行, 檀 和夫

    臨床血液   40 ( 9 )   887 - 887   1999年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 急性骨髄性白血病(AML)の微少残存病変(MRD)解析:CD15+CD117+細胞及びCD34+CD56+細胞について

    中村 恭子, 塩井 由美子, 羅 善順, 安 恵美, 横瀬 紀夫, 田近 賢二, 猪口 孝一, 緒方 清行, 檀 和夫

    臨床血液   40 ( 9 )   1003 - 1003   1999年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 急激な経過を呈したCD5陰性B-CLLの1例

    橋本 充弘, 平塚 哲郎, 山口 博樹, 横瀬 紀夫, 中村 恭子, 田近 賢二, 檀 和夫

    臨床血液   40 ( 8 )   688 - 688   1999年8月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 急性骨髄性白血病細胞の細胞周期 治療開始前後での検討

    安 恵美, 緒方 清行, 中村 恭子, 塙 圭子, 羅 善順, 塩井 由美子, 横瀬 紀夫, 猪口 孝一, 檀 和夫

    International Journal of Hematology   69 ( Suppl.1 )   87 - 87   1999年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • CD20陽性T細胞性腫瘍

    緒方 清行, 横瀬 紀夫, 塩井 由美子, 中村 恭子, 田村 秀人, 安 恵美, 山田 隆, 猪口 孝一, 檀 和夫, 杉崎 祐一

    International Journal of Hematology   69 ( Suppl.1 )   146 - 146   1999年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • 血球貪食症候群(HPS)にて発症した横紋筋原発のanaplastic large T cell lymphomaの1例

    水木 太郎, 山口 博樹, 橋本 充弘, 中村 恭子, 横瀬 紀夫, 猪口 孝一, 田近 賢二, 檀 和夫

    臨床血液   40 ( 4 )   340 - 340   1999年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 除菌終了17カ月後に13CUBT値が陰性化した胃潰瘍の1例

    伊月 葉子, 平川 恒久, 小野瀬 裕之, 横瀬 紀夫, 三宅 一昌, 津久井 拓, 香川 隆男, 坂本 長逸, 小林 正文

    消化器内視鏡の進歩：Progress of Digestive Endoscopy   53   146 - 147   1999年1月

    　詳細を見る

    記述言語：日本語   出版者・発行元：一般社団法人 日本消化器内視鏡学会 関東支部  

    This paper reports a 67-year-old man who was diagnosed as having gastric ulcer (stage A1) in January 1995. The ulcer recurred repeatedly despite treatments using PPI and other drugs. H pylori infection was detected by anti-Hp Ig-G antibody (2＋) , RUT (＋) , microscopy (＋) , and the 13CUBT (46.2‰) , so eradication therapy was performed in May 1996. The therapy consisted of a PPI (30mg/day of lansoprazole) , AMPC (1,500mg for 2 weeks) , and CAM (400mg for 2 weeks) . Although the ulcer healed to stage S1 by 4 weeks after completion of therapy, eradication was concluted to have failed because the 13CUBT was result 8.7‰ after 4 weeks and 17.5‰ after 8weeks.<br> Subsequently, an H2-blocker was administered and the ulcer healed to stage S2 in October 1997 (17 months after eradication therapy) . The 13CUBT value was 1.9‰, and RUT, microscopy, and serum anti-Ig-G antibody were all negative. In this patient, H pylori was considered to have been spontaneously cleared because he did not take medications that could eliminate the organism after the eradication therapy, except for 1,500mg of AMPC for 5 days to treat an acute upper respiratory tract infection.

    DOI： 10.11641/pdensks.53.0_146

    researchmap

    その他リンク： http://search.jamas.or.jp/link/ui/1999135890

  • 除菌終了17カ月後に13CUBT値が陰性化した胃潰瘍の1例

    伊月 葉子, 平川 恒久, 小野瀬 裕之, 横瀬 紀夫, 三宅 一昌, 津久井 拓, 香川 隆男, 坂本 長逸, 小林 正文

    消化器内視鏡の進歩：Progress of Digestive Endoscopy   53 ( 0 )   146 - 147   1999年

    　詳細を見る

    記述言語：日本語   出版者・発行元：一般社団法人 日本消化器内視鏡学会 関東支部  

    This paper reports a 67-year-old man who was diagnosed as having gastric ulcer (stage A&lt;sub&gt;1&lt;/sub&gt;) in January 1995. The ulcer recurred repeatedly despite treatments using PPI and other drugs. &lt;i&gt;H pylori&lt;/i&gt; infection was detected by anti-&lt;i&gt;Hp&lt;/i&gt; Ig-G antibody (2＋) , RUT (＋) , microscopy (＋) , and the &lt;sup&gt;13&lt;/sup&gt;CUBT (46.2‰) , so eradication therapy was performed in May 1996. The therapy consisted of a PPI (30mg/day of lansoprazole) , AMPC (1,500mg for 2 weeks) , and CAM (400mg for 2 weeks) . Although the ulcer healed to stage S&lt;sub&gt;1&lt;/sub&gt; by 4 weeks after completion of therapy, eradication was concluted to have failed because the &lt;sup&gt;13&lt;/sup&gt;CUBT was result 8.7‰ after 4 weeks and 17.5‰ after 8weeks.&lt;br&gt; Subsequently, an H&lt;sub&gt;2&lt;/sub&gt;-blocker was administered and the ulcer healed to stage S&lt;sub&gt;2&lt;/sub&gt; in October 1997 (17 months after eradication therapy) . The &lt;sup&gt;13&lt;/sup&gt;CUBT value was 1.9‰, and RUT, microscopy, and serum anti-Ig-G antibody were all negative. In this patient, &lt;i&gt;H pylori&lt;/i&gt; was considered to have been spontaneously cleared because he did not take medications that could eliminate the organism after the eradication therapy, except for 1,500mg of AMPC for 5 days to treat an acute upper respiratory tract infection.

    DOI： 10.11641/pdensks.53.0_146

    researchmap

  • 除菌終了17カ月後に13CUBT値が陰性化した胃潰瘍の1例

    伊月 葉子, 平川 恒久, 小野瀬 裕之, 横瀬 紀夫, 三宅 一昌, 津久井 拓, 香川 隆男, 坂本 長逸, 小林 正文

    消化器内視鏡の進歩：Progress of Digestive Endoscopy   53   146 - 147   1999年

    　詳細を見る

    記述言語：日本語   出版者・発行元：一般社団法人 日本消化器内視鏡学会 関東支部  

    This paper reports a 67-year-old man who was diagnosed as having gastric ulcer (stage A1) in January 1995. The ulcer recurred repeatedly despite treatments using PPI and other drugs. H pylori infection was detected by anti-Hp Ig-G antibody (2＋) , RUT (＋) , microscopy (＋) , and the 13CUBT (46.2‰) , so eradication therapy was performed in May 1996. The therapy consisted of a PPI (30mg/day of lansoprazole) , AMPC (1,500mg for 2 weeks) , and CAM (400mg for 2 weeks) . Although the ulcer healed to stage S1 by 4 weeks after completion of therapy, eradication was concluted to have failed because the 13CUBT was result 8.7‰ after 4 weeks and 17.5‰ after 8weeks.<br> Subsequently, an H2-blocker was administered and the ulcer healed to stage S2 in October 1997 (17 months after eradication therapy) . The 13CUBT value was 1.9‰, and RUT, microscopy, and serum anti-Ig-G antibody were all negative. In this patient, H pylori was considered to have been spontaneously cleared because he did not take medications that could eliminate the organism after the eradication therapy, except for 1,500mg of AMPC for 5 days to treat an acute upper respiratory tract infection.

    DOI： 10.11641/pdensks.53.0_146

    J-GLOBAL

    researchmap

  • クームス試験陰性自己免疫性溶血性貧血(AIHA)を合併し,P-glycoprotein(PGP)の発現を認めたhepatosplenic γδ T-cell lymphomaの1例

    安 恵美, 横瀬 紀夫, 橋本 充弘, 中村 恭子, 塩井 由美子, 羅 善順, 緒方 清行, 檀 和夫, 梶井 英治

    臨床血液   39 ( 10 )   1044 - 1044   1998年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • Myeloid系抗原を発現した非ホジキンリンパ腫の1例

    緒方 清行, 安 恵美, 横瀬 紀夫, 田村 秀人, 中村 恭子, 塩井 由美子, 羅 善順, 檀 和夫, 川本 雅司, 杉崎 祐一

    臨床血液   39 ( 10 )   933 - 933   1998年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 肝炎後再生不良性貧血患者の細胞性免疫に関する検討

    横瀬 紀夫, 安 恵美, 羅 善順, 田村 秀人, 中村 恭子, 塙 圭子, 塩井 由美子, 緒方 清行, 檀 和夫

    臨床血液   39 ( 10 )   962 - 962   1998年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • G-CSFにより3血球系統の回復がみられたMDSの1例

    中山 一隆, 松岡 弘樹, 横瀬 紀夫, 緒方 清行, 猪口 孝一, 檀 和夫

    老年者造血器疾患研究会会誌   7 ( 1 )   35 - 38   1998年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：老年者造血器疾患研究会  

    researchmap

  • t(1;17)核型異常を示した急性前骨髄球性白血病

    木村 祐, 猪口 孝一, 中山 一隆, 松岡 弘樹, 塙 秀樹, 田野崎 栄, 横瀬 紀夫, 安 恵美, 山田 隆, 緒方 清行

    臨床血液   39 ( 7 )   543 - 543   1998年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 予後不良因子を持つ急性骨髄生白血病(AML)の寛解持続に関する検討

    横瀬 紀夫

    International Journal of Hematology   67 ( Suppl.1 )   71 - 71   1998年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma

    N. Yokose, K. Ogata, H. Tamura, E. An, K. Nakamura, K. Kamikubo, S. Kudoh, K. Dan, T. Nomura

    British Journal of Cancer   77 ( 12 )   2286 - 2290   1998年

    　詳細を見る

    記述言語：英語   出版者・発行元：CHURCHILL LIVINGSTONE  

    Sporadic cases have developed pulmonary toxicity after receiving chemotherapy and granulocyte colony-stimulating factor (G-CSF). However, because such cases received chemotherapy that alone frequently causes pulmonary toxicity, the role of G-CSF in this toxicity has been unclear. CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) only slightly induces pulmonary toxicity. However, we observed a considerable incidence of this toxicity in non-Hodgkin's lymphoma subjects receiving CHOP therapy and G-CSF (6 out of 52 subjects, 11.5%). In this cohort, among various characteristics, including the dose and interval of CHOP therapy, only the mean peak leucocyte count (MPLC) with each therapy cycle was associated with development of this toxicity (MPLC ≤ 23.0 x 109 l-1, 6 out of 29 cases: MPLC < 23.0 x 109 l-1, 0 out of 23 cases; P = 0.020). These findings suggest that the effect of G-CSF is the main determinant of the pulmonary toxicity in these cases. Because the toxicity was associated with a large MPLC and did not recur in cases readministered G-CSF, an idiosyncratic reaction to G-CSF is unlikely to be the pathogenesis of this toxicity. Thus, lowering the G-CSF dose seems to be useful in the prevention of this toxicity. In all six cases, the time course of manifestation of the toxicity was the same, and early application of high-dose corticosteroid led to cure. This knowledge will be helpful in the care of similar cases.

    DOI： 10.1038/bjc.1998.380

    Web of Science

    Scopus

    PubMed

    researchmap

  • Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes

    H. Tamura, K. Ogata, S. Luo, K. Nakamura, N. Yokose, K. Dan, K. Tohyama, Y. Yoshida, H. Hamaguchi, H. Sakamaki, T. Kuwaki, T. Tahara, T. Kato, T. Nomura

    British Journal of Haematology   103 ( 3 )   778 - 784   1998年

    　詳細を見る

    記述言語：英語   出版者・発行元：BLACKWELL SCIENCE LTD  

    Data on endogenous thrombopoietin (TPO) levels and their regulation in myelodysplastic syndromes (MDS) are sparse. We examined the plasma TPO level of 85 MDS patients by a sensitive enzyme immunoassay and the platelet expression of TPO receptor (TPO-R) protein, which metabolizes endogenous TPO, in 19 MDS patients with an equilibrium binding assay using 125I-TPO. The MDS patients had higher plasma TPO levels (7.0 ± 9.3 fmol/ml) than 52 normal subjects (P<0.0001). Refractory anaemia (RA) patients (n = 39) had higher plasma TPO levels than patients (n = 28) with RA with excess blasts (RAEB) or RAEB in transformation (RAEB-t) (P = 0.0002), irrespective of similar platelet counts in these groups. The plasma TPO level correlated inversely with the platelet count in RA patients (P = 0.0027) but not in RAEB and RAEB- t patients (P = 0.7865). These data suggest that the physiological pathway for TPO production and metabolism is conserved, at least partially, in RA, but deranged in RAEB/RAEB-t. The number of TPO-R per platelet was significantly smaller in 19 MDS patients (17.5 ± 13.3) than in normals (P = 0.0014), but similar between RA patients and patients with RAEB and RAEB-t. Further, the bone marrow megakaryocyte count, determined in 31 MDS patients, was quite similar between RA patients and patients with RAEB or RAEB-t. Thus, in addition to thrombocytopenia, a reduced platelet TPO-R number may contribute to elevated plasma TPO levels in MDS, and a regulatory pathway for circulating TPO other than platelet TPO-R and marrow megakaryocytes, such as blasts expressing TPO-R, may operate in RAEB/RAEB-t.

    DOI： 10.1046/j.1365-2141.1998.01054.x

    Web of Science

    Scopus

    PubMed

    researchmap

  • Failure to detect anti-HTLV-1 antibody in a patient with adult T-cell leukaemia/lymphoma [2]

    S. S. Luo, H. Tamura, N. Yokose, K. Ogata, K. Dan

    British Journal of Haematology   103 ( 4 )   1207 - 1208   1998年

    　詳細を見る

    記述言語：英語   掲載種別：速報，短報，研究ノート等（学術雑誌）   出版者・発行元：BLACKWELL SCIENCE LTD  

    DOI： 10.1046/j.1365-2141.1998.1161b.x

    Web of Science

    Scopus

    PubMed

    researchmap

  • Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: A pilot study

    Kiyoyuki Ogata, A. N. Emi, Keiko Kamikubo, Norio Yokose, Hideto Tamura, Takashi Yamada, Seiji Gomi, Kazuo Dan, Takeo Nomura

    Stem Cells   16 ( 4 )   280 - 287   1998年

    　詳細を見る

    記述言語：英語   出版者・発行元：WILEY-BLACKWELL  

    The cure rate of acute myeloid leukemia might increase if G-CSF were given concurrently with repeated postremission chemotherapy. However, this therapy might cause severe complications, including depletion of normal hematopoietic progenitors as a long-term toxicity. Thus, we conducted a pilot study of this strategy. Twenty-six acute myeloid leukemia patients in a first complete remission (CR) were treated with two courses of consolidation chemotherapy (10-day BHAC-DMP, consisting of behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine and prednisolone) and repeated maintenance- intensification therapy including eight cycles of six-day BHAC-DMP. G-CSF (filgrastim) was administered concurrently with these BHAC-DMP therapies. Toxicity during the therapeutic period was not significant in the study group compared with the historical control, treated with the same regimen without G-CSF. Neutrophil recovery after the consolidation therapy was more rapid in the study group than in the historical control (p = 0.066 and 0.024 for the first and second consolidation courses, respectively). Long-term toxicity, such as cytopenia, has not been seen in eight patients who have remained in CR for a long period (range: 39-58 months). At a median follow-up of 39 months, the predicted rate of 42-month CR duration for these 26 patients was 50% (95% confidence limits: 30% to 71%). We conclude that G-CSF-combined repeated BHAC-DMP postremission therapy is feasible. Full elucidation of the clinical benefit of this strategy will require further study.

    DOI： 10.1002/stem.160280

    Web of Science

    Scopus

    PubMed

    researchmap

  • Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma

    N. Yokose, K. Ogata, H. Tamura, E. An, K. Nakamura, K. Kamikubo, S. Kudoh, K. Dan, T. Nomura

    British Journal of Cancer   77 ( 12 )   2286 - 2290   1998年

    　詳細を見る

    記述言語：英語   出版者・発行元：Nature Publishing Group  

    Sporadic cases have developed pulmonary toxicity after receiving chemotherapy and granulocyte colony-stimulating factor (G-CSF). However, because such cases received chemotherapy that alone frequently causes pulmonary toxicity, the role of G-CSF in this toxicity has been unclear. CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) only slightly induces pulmonary toxicity. However, we observed a considerable incidence of this toxicity in non-Hodgkin's lymphoma subjects receiving CHOP therapy and G-CSF (6 out of 52 subjects, 11.5%). In this cohort, among various characteristics, including the dose and interval of CHOP therapy, only the mean peak leucocyte count (MPLC) with each therapy cycle was associated with development of this toxicity (MPLC ≤ 23.0 x 109 l-1, 6 out of 29 cases: MPLC &lt
    23.0 x 109 l-1, 0 out of 23 cases
    P = 0.020). These findings suggest that the effect of G-CSF is the main determinant of the pulmonary toxicity in these cases. Because the toxicity was associated with a large MPLC and did not recur in cases readministered G-CSF, an idiosyncratic reaction to G-CSF is unlikely to be the pathogenesis of this toxicity. Thus, lowering the G-CSF dose seems to be useful in the prevention of this toxicity. In all six cases, the time course of manifestation of the toxicity was the same, and early application of high-dose corticosteroid led to cure. This knowledge will be helpful in the care of similar cases.

    DOI： 10.1038/bjc.1998.380

    Scopus

    PubMed

    researchmap

  • 赤芽球癆(PRCA)を合併した若年発症の原発性マクログロブリン血症

    横瀬 紀夫

    臨床血液   38 ( 10 )   1071 - 1071   1997年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • Natural killer cells in the late decades of human life

    Kiyoyuki Ogata, Norio Yokose, Hideto Tamura, Emi An, Kyoko Nakamura, Kazuo Dan, Takeo Nomura

    Clinical Immunology and Immunopathology   84 ( 3 )   269 - 275   1997年9月

    　詳細を見る

    記述言語：英語   出版者・発行元：ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS  

    We examined the lymphocyte subsets and indices of natural killer (NK) cell activity (lytic unit (LU), index of absolute NK cell activity in vivo (ALU), and NK cell activity on a per-cell basis (PCNK)) in 82 people (age, 30-99 years) who were immunologically normal. Although the number of NK cells was maintained throughout the examined age range, the ALU and PCNK values correlated negatively with age. We then examined whether any of the various immunologic parameters, including the function and cell counts of NK cells, T cells, and neutrophils, related to past infectious episodes and death in the follow-up period in 44 elderly subjects (age, 63-98 years). Only low ALU and PCNK values correlated with a past history of severe infection, while low LU, ALU, and PCNK values were the only parameters which correlated with death due to infection during the follow-up period. We propose that human NK cells do not escape the aging process and that a low NK cell function relates to the development of severe infections, which may be fatal, in elderly subjects.

    DOI： 10.1006/clin.1997.4401

    Web of Science

    Scopus

    PubMed

    researchmap

  • 急性骨髄性白血病(AML)の細胞増殖能に関する検討

    横瀬 紀夫

    International Journal of Hematology   65 ( Suppl.1 )   77 - 77   1997年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • Plasma soluble interleukin-2 receptors in patients with myelodysplastic syndromes

    Norio Yokose, Kiyoyuki Ogata

    Leukemia and Lymphoma   28 ( 1-2 )   171 - 176   1997年

    　詳細を見る

    記述言語：英語   出版者・発行元：HARWOOD ACAD PUBL GMBH  

    We examined the plasma soluble interleukin-2 receptor (sIL-2R) level in 80 subjects with myelodysplastic syndromes (MDS) and analyzed its correlation with hematologic/immunologic parameters and the subsequent clinical course. Compared with low-risk MDS (refractory anemia (RA) and RA with ringed sideroblasts) and normal individuals, the plasma sIL-2R level was significantly elevated in high-risk MDS (three other MDS subtypes and acute leukemia following MDS) patients. There was a significant negative correlation between the plasma sIL-2R level and the absolute counts of T and natural killer cells. Furthermore, the plasma sIL-2R level showed a significant positive correlation with the total cell mass and blast mass in particular, in the marrow, but not with the absolute count of IL-2Rα-chain-positive lymphocytes in the circulation. Fourteen of our 40 low-risk MDS subjects developed at least one of the following events during the follow-up period: erythrocyte transfusion dependence, infections requiring hospitalization, disease progression or MDS-related death. The plasma sIL-2R level was significantly higher in these patients than in event-free low-risk cases. By logistic regression analysis of various parameters in the 40 low-risk subjects, the plasma sIL-2R level was identified as a valuable independent parameter for predicting the development of events. Based on these findings, we hypothesize that the sIL-2R plays a role in the development of morbidity and mortality in MDS by inducing immunologic dysfunction.

    DOI： 10.3109/10428199709058343

    Web of Science

    Scopus

    PubMed

    researchmap

  • Cell cycle modulation by hematopoietic growth factors in myelodysplastic syndromes: Analysis by three-color flow cytometry

    K. Ogata, E. An, K. Kamikubo, H. Tamura, N. Yokose, K. Dan, T. Nomura

    Experimental Hematology   25 ( 1 )   8 - 18   1997年

    　詳細を見る

    記述言語：英語  

    Investigations of the effects of hematopoietic growth factors (HGFs) on the cell cycle of cells from myelodysplastic syndrome (MDS) have been hampered by technical difficulties. In this study, using a recently establisbed flow cytometric method that enables detailed analysis of the cell cycle (G0-, G1-, S-, and G2/M-phases) of target cells in a heterogeneous cell population, we examined the effects of granulocyte colony-stimulating factor (G-CSF) and other HGFs on the cell cycle of CD13-positive cells (blasts and other malignant myelocytic and monocytic cells) in MDS. The cell cycle response to G-CSF (decrease in G0-phase cells and increase in S-phase cells) was heterogeneous among MDS cases. When the data for 13 MDS cases and 15 de novo AML cases were compared statistically, the magnitude of cell cycle activation by G-CSF was weaker for the cells from the MDS cases. Stem cell factor, interleukin-3, or a combination of these HGFs with G-CSF reduced the G0-phase cell percentage in all examined MDS cases whose cell cycle was unresponsive to G-CSF alone. When cytosine arabinoside was added to cells with or without stimulation by HGFs, the viable G0-phase cell count was reduced in HGF-stimulated cells compared with unstimulated cells in seven of eight cases. The present results suggest that G-CSF-induced cell cycle stimulation of malignant cells can be expected in a fraction of MDS patients and that even in MDS patients whose cells do not respond to G-CSF, employment of other HGFs and their combination with G-CSF is worth consideration. The results also suggest that a well-designed therapy using HGFs and chemotherapeutic drugs may reduce the quiescent (G0) cell count in MDS, which is assumed to be responsible for drug resistance derived from cell kinetics.

    Scopus

    PubMed

    researchmap

  • Hypofibrinogenemia induced by prednisolone therapy in a patient with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia [4]

    N. Yokose, K. Ogata, K. Nakamura, K. Kamikubo, H. Tamura, E. An, K. Dan, T. Nomura

    American Journal of Hematology   55 ( 3 )   166 - 167   1997年

    　詳細を見る

    記述言語：英語   掲載種別：速報，短報，研究ノート等（学術雑誌）  

    DOI： 10.1002/(SICI)1096-8652(199707)55:3<166::AID-AJH11>3.0.CO;2-B

    Scopus

    PubMed

    researchmap

  • 顆粒球コロニー刺激因子(G-CSF)併用化学療法施行中の薬剤性間質性肺炎(IP)に関する検討

    横瀬 紀夫

    臨床血液   37 ( 10 )   1103 - 1103   1996年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • t(8; 14)(q24; q32)転座を有し,T細胞表面形質を示した非ホジキンリンパ腫

    横瀬 紀夫

    International Journal of Hematology   63 ( Suppl.1 )   194 - 194   1996年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • Autoimmune hemolytic anemia in patients with de novo acute myelocytic leukemia

    H Tamura, K Ogata, N Yokose, E An, K Kamikubo, K Dan, E Kajii, T Nomura

    ANNALS OF HEMATOLOGY   72 ( 1 )   45 - 47   1996年1月

    　詳細を見る

    記述言語：英語   出版者・発行元：SPRINGER VERLAG  

    Autoantibody against erythrocytes has occasionally been observed in patients with de novo acute myelocytic leukemia (AML), However, it is not clear whether this autoantibody in AML patients induces frank hemolysis (autoimmune hemolytic anemia, AIHA), as seen in lymphoid neoplasms. We present two de novo AML patients who showed hemolysis due to antiglobulin test-positive and test-negative AIHA, respectively. AIHA should be considered as one cause of anemia in de novo AML patients, and blood transfusions should be given carefully in such cases to avoid harmful hemolysis.

    DOI： 10.1007/BF00663016

    Web of Science

    Scopus

    PubMed

    researchmap

  • Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: A relationship with disease subtype and clinical outcome

    Kiyoyuki Ogata, Norio Yokose, Emi An, Keiko Kamikubo, Hideto Tamura, Kazuo Dan, Hisashi Sakamaki, Yasusuke Onozawa, Hiroyuki Hamaguchi, Takeo Nomura

    British Journal of Haematology   93 ( 1 )   45 - 52   1996年

    　詳細を見る

    記述言語：英語   出版者・発行元：BLACKWELL SCIENCE LTD  

    To assess the hypothesis that the plasma soluble interleukin-2 receptor (sIL-2R) level may have predictive value for morbidity/mortality in patients with myelodysplastic syndromes (MDS), we determined the plasma sIL-2R level of 80 MDS patients and examined their subsequent clinical course. Compared with low-risk MDS (refractory anaemia (RA) and RA with ringed sideroblasts) patients and normal subjects, the plasma sIL-2R level was significantly elevated in high-risk MDS (three other MDS subtypes and acute leukaemia following MDS) patients (high-risk MDS versus low-risk MDS, P < 0.01; high-risk MDS versus normal subjects, P < 0.01). 14/40 low-risk MDS patients developed at least one of the following during the follow-up period: erythrocyte transfusion dependence, infections requiring hospitalization, disease progression or MDS-related death. The plasma sIL-2R level was higher in these eventful subjects than in event-free low-risk subjects (P < 0.0001), and all of 10 low-risk subjects with a plasma sIL-2R level > 540 U/ml experienced at least one event. By logistic regression analysis of various parameters in these 40 low-risk subjects, the plasma sIL-2R level was identified as the strongest independent parameter for predicting eventful subjects (P < 0.0047). The plasma sIL-2R level did not show a predictive value in high-risk MDS. This study revealed that the plasma sIL-2R level is significantly elevated in high-risk MDS and suggested that the plasma sIL-2R level is a valuable predictive factor for the clinical outcome in low-risk MDS.

    DOI： 10.1046/j.1365-2141.1996.4641003.x

    Web of Science

    Scopus

    PubMed

    researchmap

  • CD4 lymphopenia and risk of infection in immunogerontologically healthy elderly people [5]

    K. Ogata, H. Tamura, N. Yokose, K. Dan, T. Nomura

    Lancet   347 ( 9012 )   1408 - 1408   1996年

    　詳細を見る

    記述言語：英語   掲載種別：速報，短報，研究ノート等（学術雑誌）   出版者・発行元：LANCET LTD  

    DOI： 10.1016/S0140-6736(96)91046-6

    Web of Science

    Scopus

    PubMed

    researchmap

  • ACUTE GASTRIC-MUCOSAL LESIONS ASSOCIATED WITH CYTOMEGALOVIRUS-INFECTION IN A NONIMMUNOCOMPROMISED HOST

    N YOKOSE, Y TANABE, E AN, Y OSAMURA

    INTERNAL MEDICINE   34 ( 9 )   883 - 885   1995年9月

    　詳細を見る

    記述言語：英語   掲載種別：記事・総説・解説・論説等（学術雑誌）   出版者・発行元：JAPAN SOC INTERNAL MEDICINE  

    A 75-year-old woman with epigastric pain and tarry stool was admitted to our hospital, where upper gastrointestinal endoscopic study revealed multiple gastric ulcers. The endoscopic biopsy specimens obtained on the seventh hospital day disclosed a few typical intranuclear cytomegalovirus inclusions. Cytomegalovirus-DNA was detected using polymerase chain reaction in a biopsy specimen. No immunologic abnormalities were demonstrated by any laboratory tests, While only a few cases of cytomegalovirus-associated gastric ulcer in non-immunocompromised hosts have been reported, this entity may be more frequently detected when careful histological examination is performed in the active stage rather than postponed until after healing of the ulcer.

    Web of Science

    researchmap

  • CD8,CD56陽性リンパ球のP糖蛋白発現に対するインターロイキン2(IL-2),IL-12の効果

    横瀬 紀夫

    臨床血液   36 ( 9 )   1055 - 1055   1995年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 当科における多発性骨髄腫の治療成績の検討

    横瀬 紀夫

    International Journal of Hematology   61 ( Suppl.1 )   269 - 269   1995年6月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • Effects of interleukin‐12 on natural killer cell cytotoxicity and the production of interferon‐7 and tumour necrosis factor‐a in patients with myelodysplastic syndromes

    K. OGATA, H. TAMDRA, N. YOKOSE, E. AN, K. DAN, H. HAMAGUCHI, H. SAKAMAKI, Y. ONOZAWA, S. C. CLARK, T. NOMURA

    British Journal of Haematology   90 ( 1 )   15 - 21   1995年5月

    　詳細を見る

    記述言語：英語   出版者・発行元：BLACKWELL SCIENCE LTD  

    The effects of Interleukin 12 (IL‐12) on natural killer (NK) cell cytotoxicity and on the production of interferon‐7 (IFN‐7) and tumour necrosis factor‐a (TNF‐a) were examined in 15 patients with myelodysplastic syndromes (MDS), which are well known to have immunologic defects, and in 11 normal subjects. The NK cell cytotoxicity of all of the normal subjects was augmented by incubation with IL‐12 alone, and co‐incubation with interleukin 2 (IL‐2) further augmented it (type A response). The MDS patients showed varied responses to IL‐12/IL‐2. Seven patients showed the type A response, resulting in augmented NK cell cytotoxicity which was similar to that in the normal subjects. In five other patients the cytotoxicity was not increased by IL‐12 alone, but the combination of IL‐12 and IL‐2 did augment the cytotoxicity (type B response). The augmented cytotoxicity in these type B patients was lower than that in the normal subjects. In the final three MDS patients the cytotoxicity was low and not affected by IL‐ 12 and/or IL‐2 (type C response). AH patients with refractory anaemia with excess blasts (RAEB) and patients with RAEB in transformation showed a type B or C response. Conversely, six of eight refractory anaemia patients showed a type A response. In MDS patients there was a positive correlation between the percentage of CD3CD56+ cells in pre‐incubated cells and the cytotoxicity of cells incubated with IL‐12/IL‐2. The combination of IL‐12 and IL‐2 augmented IFN‐7 and TNF‐Q production by nonadherent mononuclear cells in a synergistic or cumulative manner, respectively, in most patients. These results suggest that IL‐12, alone or with IL‐2, may modulate these important immunologic functions in most MDS patients. Copyright © 1995, Wiley Blackwell. All rights reserved

    DOI： 10.1111/j.1365-2141.1995.tb03375.x

    Web of Science

    Scopus

    PubMed

    researchmap

  • LINEAGE-UNRESTRICTED HEMATOLOGIC RESPONSE TO GRANULOCYTE-COLONY-STIMULATING FACTOR IN A PATIENT WITH REFRACTORY-ANEMIA WITH EXCESS BLASTS

    N YOKOSE, K OGATA, E AN, H TAMURA, K KAMIKUBO, K DAN, T NOMURA

    ANNALS OF HEMATOLOGY   70 ( 3 )   163 - 167   1995年3月

    　詳細を見る

    記述言語：英語   掲載種別：記事・総説・解説・論説等（学術雑誌）   出版者・発行元：SPRINGER VERLAG  

    We report a patient with refractory anemia with excess blasts who showed a lineage-unrestricted hematologic response to granulocyte colony-stimulating factor (G-CSF). After 17 months of a stable disease state, the patient developed pneumonia, progression of cytopenia, and reduced cellularity and blast mass in the bone marrow, He was given G-CSF to overcome the pneumonia. Not only the neutrophil count, but also the platelet count increased soon after initiation of the G-CSF therapy; both counts became normal on the fifth day of the G-CSF therapy. Additionally, the anemia improved gradually. The neutrophil and platelet counts were maintained in the normal range for 3 months after cessation of the G-CSF. In vitro studies showed that G-CSF alone stimulated megakaryocyte colony formation from bone marrow mononuclear cells (BMMNC), and accessory cells in the BMMNC were necessary for expression of this G-CSF-induced in vitro megakaryocytopoiesis, These results suggest that, in coordination with accessory cells, G-CSF stimulated megakaryocytopoiesis in the patient. This case provides valuable information for understanding the mechanisms of a lineage-unrestricted hematologic response to G-CSF, which is very rarely observed in MDS.

    Web of Science

    researchmap

  • LINEAGE-UNRESTRICTED HEMATOLOGIC RESPONSE TO GRANULOCYTE-COLONY-STIMULATING FACTOR IN A PATIENT WITH REFRACTORY-ANEMIA WITH EXCESS BLASTS

    N YOKOSE, K OGATA, E AN, H TAMURA, K KAMIKUBO, K DAN, T NOMURA

    ANNALS OF HEMATOLOGY   70 ( 3 )   163 - 167   1995年3月

    　詳細を見る

    記述言語：英語   掲載種別：記事・総説・解説・論説等（学術雑誌）   出版者・発行元：SPRINGER VERLAG  

    We report a patient with refractory anemia with excess blasts who showed a lineage-unrestricted hematologic response to granulocyte colony-stimulating factor (G-CSF). After 17 months of a stable disease state, the patient developed pneumonia, progression of cytopenia, and reduced cellularity and blast mass in the bone marrow, He was given G-CSF to overcome the pneumonia. Not only the neutrophil count, but also the platelet count increased soon after initiation of the G-CSF therapy; both counts became normal on the fifth day of the G-CSF therapy. Additionally, the anemia improved gradually. The neutrophil and platelet counts were maintained in the normal range for 3 months after cessation of the G-CSF. In vitro studies showed that G-CSF alone stimulated megakaryocyte colony formation from bone marrow mononuclear cells (BMMNC), and accessory cells in the BMMNC were necessary for expression of this G-CSF-induced in vitro megakaryocytopoiesis, These results suggest that, in coordination with accessory cells, G-CSF stimulated megakaryocytopoiesis in the patient. This case provides valuable information for understanding the mechanisms of a lineage-unrestricted hematologic response to G-CSF, which is very rarely observed in MDS.

    DOI： 10.1007/BF01682038

    Web of Science

    Scopus

    PubMed

    researchmap

  • Interleukin-2 therapy for myelodysplastic syndrome: Does it work?

    Kiyoyuki Ogata, Norio Yokose, Takeo Nomura

    Leukemia and Lymphoma   17 ( 5-6 )   411 - 415   1995年

    　詳細を見る

    記述言語：英語   出版者・発行元：HARWOOD ACAD PUBL GMBH  

    Recent clinical studies suggested that interleukin-2 (IL-2) has therapeutic potential for some hematologic malignancies, but the therapeutic role of IL-2 for myelodysplastic syndrome (MDS) is still unclear. MDS is a clonal malignant disorder which often involves a variety of immunologic abnormalities. Examination of the effects of IL-2 on MDS in vitro yielded the following results: (1) IL-2 did not induce the proliferation of blasts in most MDS cases. (2) The cytotoxicity of IL-2-induced lymphokine-activated killer (LAK) cells for cell lines and MDS blasts was reduced in the high-risk MDS group (refractory anemia with excess blasts (RAEB), RAEB in transformation and MDS transformed to acute leukemia), but it was still preserved in the low-risk MDS group (refractory anemia (RA) and RA with ringed sideroblasts). However, considerable variation in LAK cell cytotoxicity was noted in each group. (3) The reduced LAK cell cytotoxicity observed in MDS was explained, at least in part, by the presence of a reduced of number of natural killer (NK) cells amongst the LAK cells. (4) MDS patients who have a high blood soluble IL-2 receptor (sIL-2R) level often had defects in NK and CD8+ T cells. These in vitro findings suggest that the response to IL-2 is heterogeneous in MDS patients, and those who have a low-risk MDS subtype and/or a low blood sIL-2R level, may be prone to respond to IL-2 therapy. Clinical trials are mandatory in order to elucidate the efficacy of IL-2 therapy in the treatment of MDS. © 1995 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

    DOI： 10.3109/10428199509056851

    Web of Science

    Scopus

    PubMed

    researchmap

  • 骨髄異形成症候群(MDS)の血中マクロファージコロニー刺激因子(M-CSF)に関する検討

    横瀬 紀夫

    臨床血液   35 ( 10 )   1108 - 1108   1994年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • ELEVATED PLASMA SOLUBLE INTERLEUKIN-2 RECEPTOR LEVEL CORRELATES WITH DEFECTIVE NATURAL-KILLER AND CD8+ T-CELLS IN MYELODYSPLASTIC SYNDROMES

    N YOKOSE, K OGATA, T ITO, EM AN, H TAMURA, KZ DAN, H HAMAGUCHI, H SAKAMAKI, Y ONOZAWA, T NOMURA

    LEUKEMIA RESEARCH   18 ( 10 )   777 - 782   1994年10月

    　詳細を見る

    記述言語：英語   出版者・発行元：PERGAMON-ELSEVIER SCIENCE LTD  

    The plasma soluble interleukin 2 receptor (sIL-2R) level and its relationships with haematologic and immunologic data were examined in 40 patients with myelodysplastic syndromes (MDS). The plasma sIL-2R level was significantly higher in the high-risk MDS group (refractory anaemia with excess blasts (RAEB), RAEB in transformation and chronic myelomonocytic leukaemia) than in the low-risk MDS group (refractory anaemia (RA) and RA with ringed sideroblasts) or in normal subjects, although there was considerable variation in the plasma sIL-2R level within each MDS group. The plasma sIL-2R level correlated positively with the bone marrow cellularity and bone marrow blast mass, but not with the absolute number of CD25+ lymphocytes. This may support the idea that plasma sIL-2R is derived from malignant MDS cells in the bone marrow. The plasma sIL-2R level correlated negatively with the absolute numbers of the CD8+, CD3-CD16+, and CD3-CD56+ cell populations in freshly isolated lymphocytes, the percentage of CD3-CD56+ cells in lymphokine (interleukin 2)-activated killer (LAK) cells, and the cytotoxicity of LAK cells. We conclude that MDS patients having a high plasma sIL-2R level often have a defect in natural killer and CD8+ T-cells.

    Web of Science

    researchmap

  • 骨髄異形成症候群の血中可溶性CD8(sCD8)と可溶性インターロイキン2受容体(sIL-2R)に関する検討

    横瀬 紀夫

    International Journal of Hematology   59 ( Suppl.1 )   170 - 170   1994年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • 高齢者肝癌に関する臨床的検討

    横瀬紀夫, 広田黛, 成沢慶哉, 永井俊彦

    多摩消化器シンポジウム誌   8 ( 1 )   34 - 41   1994年3月

    　詳細を見る

    記述言語：日本語   出版者・発行元：多摩消化器シンポジウム  

    最近6年間に経験した65歳以上の原発性肝癌(HCC)29例,転移性肝癌(MLC)60例の背景因子,検査成績,経過,予後等について検討した.HCCの89.7%は慢性肝疾患を合併しており,HCV抗体陽性率は70.6%,HBs抗原陽性は6.9%.腫瘍マーカーではPIVKA-II上昇例は少なく,AFP高値例(10,000ng/ml以上)に限られた.MLCの原発巣は半数以上が消化管で,原発巣との同時診断例が70%.HCCの平均生存期間19.9ヵ月に対し,MLCでは6.1ヵ月で,12ヵ月以上生存は4例のみだったが,これは原発巣切除に加え肝腫瘍に対し切除術又は抗癌剤動注を行ったものであった

    J-GLOBAL

    researchmap

  • 骨髄異形成症候群(MDS)の免疫異常 血中可溶性インターロイキン2受容体(sIL-2R)とナチュラルキラー(NK)細胞・T細胞不全との関連について

    横瀬 紀夫

    日本内科学会雑誌   83 ( 臨増 )   111 - 111   1994年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本内科学会  

    researchmap

  • Aplastic anemia with circulating erythroblasts

    N. Yokose, K. Ogata, K. Dan, T. Nomura

    International Journal of Hematology   60 ( 2 )   111 - 117   1994年

    　詳細を見る

    記述言語：英語   出版者・発行元：ELSEVIER SCI IRELAND LTD  

    Since the presence of erythroblasts (Ebl) in the peripheral blood of patients suspected to have aplastic anemia (AA) has been thought to suggest an error in diagnosis, such patients may not receive appropriate therapy promptly, with potentially fatal results. However, we recently experienced patients who had the typical features of AA except for circulating Ebl, and responded well to therapy for AA. In this study, we examined 55 untreated AA patients for the presence of circulating Ebl. Seven patients (12.7%) had circulating Ebl (at least one Ebl per 200 leukocytes counted). These seven patients showed the typical features of AA. There were no significant differences in age or hematologic parameters, including the morphology of bone marrow Ebl, between the AA patients having circulating Ebl (Ebl(+) AA) and the AA patients without Ebl. All but one of the Ebl(+) AA patients responded well to the therapy for AA. During 12.0-110.4 months of follow-up, transformation to other diseases did not occur, and all seven patients were alive. We conclude that circulating Ebl are not rare in patients who have otherwise typical features of AA, and that if such Ebl(+) AA patients are severely cytopenic, they should receive treatment for AA without delay.

    Web of Science

    Scopus

    PubMed

    researchmap

  • Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes

    Norio Yokose, Kiyoyuki Ogata, Toshiharu Ito, Emi An, Hideto Tamura, Kazuo Dan, Hiroyuki Hamaguchi, Hisashi Sakamaki, Yasusuke Onozawa, Takeo Nomura

    Leukemia Research   18 ( 10 )   777 - 782   1994年

    　詳細を見る

    記述言語：英語  

    The plasma soluble interleukin 2 receptor (sIL-2R) level and its relationships with haematologic and immunologic data were examined in 40 patients with myelodysplastic syndromes (MDS). The plasma sIL-2R level was significantly higher in the high-risk MDS group (refractory anaemia with excess blasts (RAEB), RAEB in transformation and chronic myelomonocytic leukaemia) than in the low-risk MDS group (refractory anaemia (RA) and RA with ringed sideroblasts) or in normal subjects, although there was considerable variation in the plasma sIL-2R level within each MDS group. The plasma sIL-2R level correlated positively with the bone marrow cellularity and bone marrow blast mass, but not with the absolute number of CD25+ lymphocytes. This may support the idea that plasma sIL-2R is derived from malignant MDS cells in the bone marrow. The plasma sIL-2R level correlated negatively with the absolute numbers of the CD8+, CD3-CD16+, and CD3-CD56+ cell populations in freshly isolated lymphocytes, the percentage of CD3-CD56+ cells in lymphokine (interleukin 2)-activated killer (LAK) cells, and the cytotoxicity of LAK cells. We conclude that MDS patients having a high plasma sIL-2R level often have a defect in natural killer and CD8+ T-cells. © 1994.

    DOI： 10.1016/0145-2126(94)90060-4

    Scopus

    PubMed

    researchmap

  • Defective natural killer (NK) cell-mediated cytotoxicity does not imply clonal involvement of NK cells in myelodysplastic syndromes

    K. Ogata, H. Fujii, N. Yokose, E. An, H. Tamura, K. Kamikubo, K. Dan, H. Hamaguchi, H. Sakamaki, Y. Onozawa, T. Nomura

    British Journal of Haematology   87 ( 2 )   396 - 398   1994年

    　詳細を見る

    記述言語：英語   出版者・発行元：BLACKWELL SCIENCE LTD  

    The clonality of purified cells was examined in 10 myelodysplastic syndromes (MDS) patients by analysing the restriction fragment length polymorphism and methylation pattern of the phosphoglycerate-kinase gene. Natural killer (NK) cell-mediated cytotoxicity was also examined. The granulocytes and monocytes were monoclonal or oligoclonal in all cases, except for the monocytes in one case. Conversely, the NK and T cells had a polyclonal pattern in most cases, including all cases who had defective NK cell-mediated cytotoxicity. The hypothesis that reduced NK cell-mediated cytotoxicity in MDS is caused by a clonal involvement of NK cells was not supported by the present study.

    DOI： 10.1111/j.1365-2141.1994.tb04928.x

    Web of Science

    Scopus

    PubMed

    researchmap

  • A Case of Hemorrhage due to Portal Hypertensive Gastropathy Successfully Treated with Transjugular Intrahepatic Portosystemic Shunt

    Hidenori Kanazawa, Masashi Yoshizawa, Hitoshi Saitou, Katsuhisa Nakatsuka, Norio Yokose, Haruki Hoshinaga, Atsushi Watari, Satoshi Matsusaka, Norihiko Tada, Hajime Kuroda, Masafumi Kobayashi, Takeo Nomura

    GASTROENTEROLOGICAL ENDOSCOPY   36 ( 4 )   793 - 799   1994年

    　詳細を見る

    記述言語：英語   出版者・発行元：一般社団法人 日本消化器内視鏡学会  

    A 43-year-old man was admitted for variceal bleeding due to alcoholic cirrhosis. Bleeding from esophageal varices was controlled after 3 sessions of endoscopic sclerotherapy. But hemorrhage from portal hypertensive gastropathy was occurred after sclerotherapy and was not controlled by medical treatment. An emergency transjugular intrahepatic portosystemic shunt was successfully performed and a subsequent arrest of acute hemorrhage. Transjugular intrahepatic portosystemic shunt may become an useful treatment for hemorrhage from portal hypertensive gastropathy. © 1994, Japan Gastroenterological Endoscopy Society. All rights reserved.

    DOI： 10.11280/gee1973b.36.793

    Scopus

    J-GLOBAL

    researchmap

  • 診断時末梢血中に赤芽球を認め現在まで再生不良性貧血として経過を追っている症例の臨床的検討

    横瀬 紀夫

    臨床血液   34 ( 10 )   1356 - 1356   1993年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 骨髄異形成症候群患者血清の正常リンパ球におよぼす作用 可溶性IL-2受容体とリンパ球の抗腫瘍作用との関連

    横瀬 紀夫

    International Journal of Hematology   57 ( Suppl.1 )   116 - 116   1993年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • CHEMOTHERAPY FOR MINIMALLY DIFFERENTIATED ACUTE MYELOID-LEUKEMIA (AML-M0) - A REPORT ON 5 CASES AND REVIEW OF THE LITERATURE

    N YOKOSE, K OGATA, T ITO, K MIYAKE, E AN, K INOKUCHI, T YAMADA, S GOMI, Y TANABE, OHKI, I, T KUWABARA, S HASEGAWA, T SHINOHARA, K DAN, T NOMURA

    ANNALS OF HEMATOLOGY   66 ( 2 )   67 - 70   1993年2月

    　詳細を見る

    記述言語：英語   出版者・発行元：SPRINGER VERLAG  

    With the objective of establishing the optimal therapy for minimally differentiated acute myeloid leukemia (AML-M0), we examined the therapeutic results of five AML-M0 cases and reviewed the literature. In a series of 63 patients with newly diagnosed acute leukemia who were admitted to the Main Hospital of Nippon Medical School, five patients fit the criteria for AML-M0: negative myeloperoxidase (MPO) and Sudan black B reaction by light microscopy, negative for B- and T-lineage markers, and positive for myeloid markers. They were treated by means of AdVP [adriamycin, vincristine, and prednisolone (PSL)] therapy and/or BHAC-DMP [behenoylcytosine arabinoside (BHAC), daunorubicin (DNR), 6-mercaptopurine (6-MP), and PSL] therapy. The AdVP therapy was unsuccessful in the two patients who received it, while a complete remission (CR) was achieved with the BHAC-DMP therapy in three of four patients. Although one patient treated with BHAC-DMP did not achieve CR, his blasts were apparently sensitive to the therapy. In assessable cases in the literature where leukemic blasts were MPO-negative, myeloid marker-positive and B- and T-lineage marker-negative, CR was achieved in 54.5% and 44.4% with anti-acute myeloid leukemia therapy and anti-acute lymphocytic leukemia therapy, respectively. Five cases in the literature were treated with a chemotherapeutic regimen containing BHAC [or cytosine arabinoside (Ara-C)], DNR, and 6-MP, and all achieved CR. The regimen containing BHAC (or Ara-C), DNR, and 6-MP may be useful as induction chemotherapy for AML-M0.

    DOI： 10.1007/BF01695886

    Web of Science

    Scopus

    PubMed

    researchmap

  • CHEMOTHERAPY FOR MINIMALLY DIFFERENTIATED ACUTE MYELOID-LEUKEMIA (AML-M0) - A REPORT ON 5 CASES AND REVIEW OF THE LITERATURE

    N YOKOSE, K OGATA, T ITO, K MIYAKE, E AN, K INOKUCHI, T YAMADA, S GOMI, Y TANABE, OHKI, I, T KUWABARA, S HASEGAWA, T SHINOHARA, K DAN, T NOMURA

    ANNALS OF HEMATOLOGY   66 ( 2 )   67 - 70   1993年2月

    　詳細を見る

    記述言語：英語   出版者・発行元：SPRINGER VERLAG  

    With the objective of establishing the optimal therapy for minimally differentiated acute myeloid leukemia (AML-M0), we examined the therapeutic results of five AML-M0 cases and reviewed the literature. In a series of 63 patients with newly diagnosed acute leukemia who were admitted to the Main Hospital of Nippon Medical School, five patients fit the criteria for AML-M0: negative myeloperoxidase (MPO) and Sudan black B reaction by light microscopy, negative for B- and T-lineage markers, and positive for myeloid markers. They were treated by means of AdVP [adriamycin, vincristine, and prednisolone (PSL)] therapy and/or BHAC-DMP [behenoylcytosine arabinoside (BHAC), daunorubicin (DNR), 6-mercaptopurine (6-MP), and PSL] therapy. The AdVP therapy was unsuccessful in the two patients who received it, while a complete remission (CR) was achieved with the BHAC-DMP therapy in three of four patients. Although one patient treated with BHAC-DMP did not achieve CR, his blasts were apparently sensitive to the therapy. In assessable cases in the literature where leukemic blasts were MPO-negative, myeloid marker-positive and B- and T-lineage marker-negative, CR was achieved in 54.5% and 44.4% with anti-acute myeloid leukemia therapy and anti-acute lymphocytic leukemia therapy, respectively. Five cases in the literature were treated with a chemotherapeutic regimen containing BHAC [or cytosine arabinoside (Ara-C)], DNR, and 6-MP, and all achieved CR. The regimen containing BHAC (or Ara-C), DNR, and 6-MP may be useful as induction chemotherapy for AML-M0.

    Web of Science

    researchmap

  • 6;9転座を認めた急性白血病の2例

    伊藤 敏治, 緒方 清行, 五味 聖二, 山田 隆, 田辺 義博, 大木 一郎, 長谷川 節雄, 檀 和夫, 野村 武夫, 篠原 多美子, 陶山 幸二, 塚原 理歌, 松岡 弘樹, 横瀬 紀夫, 三宅 弘一, 安 恵美, 二木 真琴, 猪口 孝一

    臨床血流   34 ( 1 )   50 - 56   1993年1月

    　詳細を見る

    記述言語：日本語   掲載種別：書評論文，書評，文献紹介等   出版者・発行元：一般社団法人 日本血液学会  

    6;9転座を示した急性白血病の2例を報告し，既報の31例と併せて文献的考察を加えた。症例1, 34歳女性。AML-M1と診断，染色体分析にてt(6;9)(p23;q34)を認めた。BHAC-DMP療法を2コース施行し完全寛解を得た。1年9カ月後に死亡した。症例2, 46歳男性。肺炎，肝障害で入院。RAEBと診断，染色体分析にてt(6;9)(p23;q34)を認めた。3カ月後に急性白血病に移行し，同時に右下腿に白血病細胞の浸潤を伴う広範な皮膚潰瘍が出現した。Ara-C少量療法を4コース行ったが寛解に至らず，続いて行った2コースのVP-16少量療法にて完全寛解となった。4カ月後に再発し敗血症で死亡した。当科の症例と併せた33例の検討では，M1 4例，M2 13例，M4 9例，RAEB 6例 急性骨髄線維症1例である。骨髄好塩基球の増加を認めた例は24例中14例である。初回寛解導入に成功した例は32例中17例であり，平均生存期間は10カ月である。

    DOI： 10.11406/rinketsu.34.50

    Scopus

    PubMed

    J-GLOBAL

    researchmap

  • Effects of interleukin 2 on myelodysplastic syndromes

    Kiyoyuki Ogata, Norio Yokose, Toshiharu Ito, Emi An, Kazuo Dan, Takeo Nomura

    Leukemia Research   17 ( 2 )   137 - 142   1993年

    　詳細を見る

    記述言語：英語  

    To evaluate the clinical usefulness of interleukin 2 (IL-2) on myelodysplastic syndromes (MDS), the serum IL-2 level, the effect of IL-2 on the proliferation of blasts, and the cell-mediated cytotoxic effect of IL-2 on blasts were examined in MDS patients. Of 18 patients, 2 patients had an increased serum IL-2 level. Although the proliferation of blasts in most cases, including the two patients having a high serum IL-2 level, was not stimulated by IL-2, the blasts of one case apparently proliferated in response to IL-2. It was also clearly shown that IL-2-stimulated normal peripheral blood mononuclear cells (PBMNC) showed cytotoxicity against MDS blasts, whereas the PBMNC of the advanced stages of MDS were usually defective in regard to this IL-2-dependent cytotoxicity. The therapeutic usefulness of IL-2 or lymphokine-activated killer cells for MDS was not established by the present study. © 1993.

    DOI： 10.1016/0145-2126(93)90058-S

    Scopus

    PubMed

    researchmap

  • MDSの病態と血中IL-2およびsIL-2Rとの関連

    横瀬 紀夫

    臨床血液   33 ( 10 )   1499 - 1499   1992年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 若年女子心筋梗塞の臨床像, 冠動脈・左室造影所見の特徴(日本循環器学会 第138回関東甲信越地方会)

    横瀬 紀夫, 中込 明裕, 今泉 孝敬, 説田 浩一, 富田 喜文, 清野 精彦, 田中 啓治, 高野 照夫, 浅井 邦也, 安武 正弘, 畑 典武, 宗像 一雄, 早川 弘一

    Japanese circulation journal   56 ( 0 )   775 - 775   1992年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：社団法人日本循環器学会  

    CiNii Books

    researchmap

  • 未分化急性骨髄性白血病(AML-MD)の臨床像の特徴

    横瀬 紀夫

    International Journal of Hematology   55 ( Suppl.1 )   95 - 95   1992年4月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会  

    researchmap

  • MDSに対するIL-2療法の可能性

    横瀬 紀夫

    日本内科学会雑誌   81 ( 臨増 )   252 - 252   1992年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本内科学会  

    researchmap

  • エトポシド少量療法が奏効した高齢者MDSの1例

    横瀬 紀夫, 緒方 清行, 三宅 弘一

    老年者造血器疾患研究会講演集   ( 6 )   19 - 22   1991年11月

    　詳細を見る

    記述言語：日本語   出版者・発行元：住友製薬(株)  

    researchmap

  • MDS芽球に対するインターロイキン2の効果

    横瀬 紀夫

    臨床血液   32 ( 10 )   1326 - 1326   1991年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap

  • 直腸神経線維腫の1例

    横瀬 紀夫

    日本消化器病学会雑誌   88 ( 臨増 )   2412 - 2412   1991年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一財)日本消化器病学会  

    researchmap

  • 直腸神経線維腫の1例

    天野康雄, 片山信仁, 横瀬紀夫, 山本彰, 林宏光, 玉井仁, 隈崎達夫, 恵畑欣一

    臨床放射線   36 ( 5 )   615 - 618   1991年

    　詳細を見る

    記述言語：日本語   出版者・発行元：金原出版(株)  

    Scopus

    J-GLOBAL

    researchmap

▼全件表示

共同研究・競争的資金等の研究課題

  • 老化によるナチュラルキラー細胞活性の低下に関する基礎的検討

    研究課題/領域番号：12770241  2000年 - 2001年

    日本学術振興会  科学研究費助成事業  奨励研究(A)

    横瀬 紀夫

    　 詳細を見る

    配分額：1700000円 （ 直接経費：1700000円 ）

    フローサイトメーター(FCM)による検討では、若年者、高齢者のNK細胞表面のFas ligand(FasL)発現を検出できなかった。FasLの細胞表面からの遊離を阻害する蛋白分解酵素阻害剤存在下の検討でも同様であった。MACSを用いて純化したNK細胞のCD95陽性Jurkat細胞に対するapoptosis誘導能の解析を混合培養系で行った。手法は^3H-thymidine標識のJurkat細胞をtargetとしたcytotoxic assay(Proc. Natl. Acad. Sci USA 94 : 5860-65,1997)、および、FCMを用いたJurkat細胞に対するannexinV発現誘導測定の2種類を用いたが、いずれの方法でもNK細胞に有意なFasL活性は認められなかった。特に^3H-thymidine標識のJurkat細胞をtargetとしたcytotoxic assayについては、過去の報告と同条件または条件を変えて、末梢血単核球(PBMNC)のFasL活性を測定してみたところ、論文とは異なりPBMNCのFasL活性は検出できなかったことから、assay系になんらかの問題があることが考えられた。今後はNK細胞の細胞内FasL発現の測定を行ない若年者、高齢者間で比較検討を行う予定である。また、FasL活性を安定して測定できる系の確立が本研究にとっては重要であり、今後も検討を重ねていく必要がある。なお、これまでに採血を行ってきた高齢者についてそのNK活性と感染症発症の有無を臨床的に検討したところ、performance status不良な高齢者において、低NK活性と、感染症発症および感染症死の間に相関があることが示された。

    researchmap

  • Clinical study of hematological diseases and hematological malignancy

    　 詳細を見る

    資金種別：競争的資金

    researchmap

  • 血液疾患・造血器腫瘍の臨床的検討

    　 詳細を見る

    資金種別：競争的資金

    researchmap